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Summary 
Introduction: Pharmacodynamic (PD) biomarkers provide proof-of-principle of target modulation 
and evaluate downstream biological effects of novel targeted therapeutics. PD biomarkers 
accelerate drug development and the transition of new drugs into the clinic. Neuroblastoma is a 
high-risk childhood cancer in which bone marrow metastases are frequent. The aim of this study 
was to develop PD biomarkers of the phosphoinositide-3-kinase (PI3K)/AKT pathway to 
accompany early clinical trials of molecularly targeted agents. This research included: 1) the 
adaptation of a surrogate biomarker assay of the PI3K/AKT pathway in platelet-rich plasma (PRP), 
2) the development of a technique to isolate tumour cells from bone marrow aspirates for PD 
biomarker assays, 3) the development of a quantitative ELISA to measure MYCN protein 
expression (a downstream effector of PI3K) and 4) the development of assays to measure the 
PI3K/AKT pathway in tumour cells isolated from bone marrow samples. 
Material and Methods: MesoScale Discovery (MSD) ® Triplex AKT assay (total and phospho 
protein signals for AKT, GSK3  and p70S6K) was used in PRP and tumour cells, tumour cells 
were isolated using immunomagnetic separation methods based on MicroBeads from the bone 
marrow. A Europium-based ELISA was developed to quantify MYCN oncoprotein. Pre-clinical 
testing was performed with neuroblastoma cell lines spiked in healthy volunteer blood samples. 
Clinical testing was performed in 14 children with advanced solid tumours, 5 of them with 
neuroblastoma metastatic to the bone marrow. The study had Royal Marsden Hospital institutional 
approval.  
Results: Detectable signal for all total and phospho proteins was found in all cases with the MSD ® 
Triplex AKT assay in PRP. No differences according to age, diagnosis or stage were found. CD45 
depletion was superior to GD2 positive selection in isolating neuroblastoma cells from bone 
marrow aspirates and obtained cell suspensions with high purity of neuroblastoma cells in spiking 
experiments in peripheral blood and in bone marrow samples from children with neuroblastoma 
metastatic to the bone marrow. Cell suspensions contained sufficient amounts of protein for 
subsequent analyses. A sensitive and specific Europium-based ELISA was developed to quantify 
total MYCN oncoprotein levels. The MSD ® Triplex AKT assay was able to measure PI3K pathway 
activation in neuroblastoma cells in the bone marrow in a pre- clinical situation.  
Discussion and conclusions: The PRP assay has been validated in the paediatric population 
and is ready to be implemented in early clinical trials in children as a pharmacodynamic biomarker 
in the upcoming paediatric first-in-child studies of the dual PI3K/mTOR inhibitors BEZ235 and 
GDC0980. Immunomagnetic separation with CD45 depletion was found to be an effective 
technique to obtain pure cell suspensions of neuroblastoma cells as a non-invasive source of 
tumour cells for protein pharmacodynamic biomarker assays. The pre-clinical development phase 
of the MYCN ELISA has been completed and this will move to clinical development prior to the 
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implementation of the clinical trials. The pre-clinical development phase of the MSD® PI3K/AKT 
assay in neuroblastoma cells was completed and this will move to clinical development. The 
development and implementation of these biomarkers in new biological hypothesis-driven first-in-
child phase I clinical trials will lead to better drugs taken forward into phase II/III trials and 
eventually into clinical practice.   
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Resumen en español 
Introducción: Los biomarcadores farmacodinámicos (PD) se utilizan para demostrar inhibición 
farmacológica de dianas terapéuticas, así como para evaluar los efectos en las cascadas de 
señalización intracelular de los nuevos tratamientos contra dianas moleculares. Los 
biomarcadores farmacodinámicos aceleran el desarrollo de nuevos fármacos y la transición de 
nuevos fármacos hasta su uso clínico. El neuroblastoma es un tumor infantil de alto riesgo en el 
que las metástasis de médula ósea son frecuentes. El objetivo de este estudio fue desarrollar 
biomarcadores farmacodinámicos de la vía de señalización fosfoinositil-trifosfato-kinasa 
(PI3K)/AKT que puedan ser implementados en ensayos clínicos fase I/II de terapias moleculares, 
incluyendo: 1) la adaptación de un biomarcador indirecto de la vía de señalización PI3K/AKT en 
plasma enriquecido con plaquetas (PRP), 2) el desarrollo de la metodología para aislar células 
tumorales de muestras de aspirado de médula ósea para su uso en biomarcadores proteicos, 3) el 
desarrollo de un ELISA cuantitativo para medir la expresión de la proteína MYCN en 
neuroblastoma (un efector de PI3K) y 4) el desarrollo de técnicas para medir la vía de señalización 
PI3K/AKT directamente en células tumorales aisladas de muestras de medula ósea.  
Material y métodos: Las señales de proteínas total y fosforilada AKT, GSK3  y p70S6K en 
plasma enriquecido con plaquetas y células tumorales fueron medidas con la tecnología 
MesoScale Discovery (MSD) ® Triplex AKT. La separación de células tumorales se realizó con 
métodos de separación inmunomagnética basados en MicroBeads y se desarrollo un ELISA 
utilizando Europium para cuantificar la expresión de proteína MYCN total. El desarrollo pre-clínico 
se realizo en células de neuroblastoma provenientes de líneas celulares diluidas en sangre 
periférica de voluntarios sanos. El desarrollo clínico se realizó en 14 niños con tumores sólidos 
avanzados, cinco de ellos con neuroblastoma metastásico en la médula ósea. El estudio se realizo 
con autorización del Comité de Investigación Clínica del Hospital Royal Marsden.  
Resultados: El estudio de los biomarcadores realizados en plasma enriquecido con plaquetas 
permitió mostrar señales detectables para todas las proteínas totales y fosforiladas en todos los 
casos. No se encontraron diferencias respecto a edad, diagnostico o estadio. La depleción de 
células CD45+ fue el método de separación inmunomagnética superior, obteniendo suspensiones 
celulares con alta pureza en células de neuroblastoma en experimentos con líneas celulares de 
neuroblastoma en sangre periférica y en muestras de médula ósea de pacientes con afectación 
metastásica por neuroblastoma. Las suspensiones celulares obtenidas contenían suficiente 
cantidad de proteína para los biomarcadores requeridos. Se desarrollo un sandwich ELISA basado 
en Europio para medir la expresión de proteína MYCN total de forma sensible y especifica. Se 
completo el desarrollo preclínico de la tecnología MSD Triplex AKT para medir la activación de la 
vía de señalización PI3K/AKT en células de neuroblastoma. 
Pharmacodynamic biomarkers in neuroblastoma, Lucas Moreno, January 2012 
13 
Discusión y conclusiones: los biomarcadores en plasma enriquecido con plaquetas han sido 
validados en la población pediátrica y están completamente preparados para ser implementados 
como biomarcadores farmacodinámicos en los ensayos clínicos de fase I en pacientes pediátricos 
de los inhibidores duales de PI3K y mTOR BEZ235 y GDC0980 de próxima apertura en el Hospital 
Royal Marsden. La separación inmunomagnética con depleción de células CD45 demostró ser 
una metodología efectiva para obtener suspensiones celulares purificadas en células de 
neuroblastoma como una fuente no invasiva de células tumorales para biomarcadores 
farmacodinámicos proteicos. El desarrollo preclínico del ELISA para MYCN fue completado 
permitiendo su transición a la fase clínica. Se realizó el desarrollo preclínico piloto de la tecnología 
MSD para PI3K/AKT en células de neuroblastoma y la tecnología será evaluada en la fase clínica. 
El desarrollo e implementación de dichos biomarcadores en nuevos ensayos clínicos fase I 
basados en hipótesis biológicas llevara a una mejoría en la selección de fármacos que se 
transfieren a ensayos fase II y III y eventualmente a la práctica clínica.  
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1. Neuroblastoma 
1.1 Metastatic and MYCN amplified neuroblastoma is a childhood cancer with poor 
prognosis 
Neuroblastoma is a tumour derived from the sympathetic nervous system and is the most common 
solid tumour in children. The German pathologist R.L.K. Virchow first described the histological 
appearance in 1864. In 1910 J.H. Wright used the term ‗neuroblastoma‘ [1-2]. A wide clinical 
spectrum has been described from tumour regression and maturation to ganglioneuroma in 
localised and infant tumours [3-4] to metastatic and MYCN amplified forms, which although usually 
are initially chemosensitive eventually recur in a drug resistant form [5-6].  
Although the prognosis for paediatric cancer has improved significantly over past decades, 
childhood cancer is still the principal cause of death from disease between infancy and adulthood 
in developed countries and 25% of children with cancer die from their disease. According to 
EUROCARE database, there are approximately 400 cases of neuroblastoma per year across 
Europe [7]. 
Around half of cases present at advanced stages or have adverse biologic features. Those patients 
have a high rate of relapses accounting for 15% of deaths from childhood cancer [8-9]. High-risk 
neuroblastoma comprises children with stage M (metastatic) disease or MYCN amplification [10]. 
After current first line treatment including multimodal treatment with chemotherapy, surgery, high-
dose chemotherapy with haematopoietic stem cell rescue, radiotherapy to the site of the primary 
tumour and differentiating therapy, more than 70% of patients experience relapse [6]. Recently, the 
addition of immunotherapy to treat residual disease has increased event free survival and reduced 
relapse by 20% [11-12]. Outcome after relapse or progression is dismal if the patient has 
previously received high-dose chemotherapy with haematopoietic stem cell rescue [13-14]. These 
patients define a cohort of children in whom conventional therapy is not successful with 5-year 
overall survival below 8%. In a study by the Italian Neuroblastoma Registry, 10-year overall 
survival was 2% after relapse of high-risk neuroblastoma [15]. Therefore, there is an unmet need to 
develop new drugs for children with high-risk neuroblastoma.  
 
1.2 MYCN amplification in neuroblastoma 
Amplification of the MYCN oncogenes (V-myc myelocytomatosis viral related oncogene, 
neuroblastoma derived), located on chromosome 2p24 was initially described by Schwab et al. [16]. 
MYCN oncogene amplification is among the best-characterised genomic markers available for risk-
based therapeutic classification and in multifactorial analysis identifies patients with neuroblastoma 
with a poor prognosis [17-18] regardless of their stage.  
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In addition to human neuroblastoma where it is found in approximately 25% of tumours, MYCN 
amplification has also been reported in a number of other tumours, including alveolar 
rhabdomyosarcoma (60%), retinoblastoma (20%), medulloblastoma (10%) and in adults, small cell 
lung cancer (7%) [19]. Aberrations in the expression of MYC gene family members (c-myc and 
MYCN) contribute also to other adult malignancies (Burkitt‘s and non-Hodgkin‘s lymphoma) and 
several paediatric solid tumours. 
Normal MYCN expression is restricted to early stages of embryonic development. Targeted 
homozygous deletion of MYC or MYCN in mice results in embryonic lethality, while transgenic 
mouse models of MYC and MYCN overexpression have been developed harbouring the same 
genetic profile than human tumours (i.e. 17q). Those mice have been found to develop a range of 
tumours, suggesting they play a crucial role in both embryonic and oncogenic development [20]. 
The MYC family members are transcription factors. MYC proteins activate the transcription of a 
number of target genes [19, 21]. 
 
1.3 MYCN as a therapeutic target 
Due to its central role in neuroblastoma genesis and potent oncogenic stimulus, MYCN is an 
attractive target for the development of new anticancer drugs.  
MYCN amplification is translated into increased levels of MYCN oncoprotein which has effects in 
cell proliferation, angiogenesis, differentiation and invasive potential. Therefore, MYCN and MYCN 
are potential targets for a number of MYCN-driven malignancies. Although it is not clear if a 
specific MYCN inhibitor would be effective, different approaches at several steps from gene to 
protein level have been studied and results are encouraging [21]. 
Several decades ago, attempts of targeting MYCN with antisense DNA were successfully 
performed in pre-clinical models [22-23] although this approach did not succeed in the clinic. 
Several candidate genes that are directly or indirectly regulated by MYCN can be targeted with 
new molecules that are in pre-clinical or clinical development. Examples of these direct or indirect 
targets are MDM2 (murine double minute oncogenes, via the p53 pathway), DKK3 (Dickkopf-
related protein 3 via Wnt inhibition), SKP2 (S-phase kinase-associated protein 2 via proteasome 
inhibition) and Aurora kinase A [21].  
More recently, it has been shown that phosphorylation of MYCN protein causes destabilization and 
proteosomal degradation of the protein and reversal of its deleterious effects. Several targeted 
agents inhibiting different pathways such as Phosphoinositide 3-kinase (PI3K), AKT, mammalian 
target of rapamycin (mTOR), cycline dependent kinase (CDK) and Aurora kinases are able to 
phosphorylate MYCN and this is a field of very active research at the moment. Chesler et al. 
showed that pharmacologic inhibition of PI3K in transgenic TH-MYCN models decreased the levels 
of MYCN protein and decreased tumour growth [24]. They were able to demonstrate that PI3K 
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inhibition with LY294002, a pure PI3K inhibitor blocked MYCN at post-transcriptional level and 
diminished the levels of MYCN protein. This occurred via activation of GSK3β which 
phosphorylates MYCN and destabilizes the protein.  
Chesler et al. hypothesized that neuroblastoma tumours with MYCN amplification are ―addicted‖ to 
MYCN oncoprotein and that pharmacological blockage of this pathway will result in excellent anti-
tumour effects [24]. This hypothesis has been tested in genetically engineered murine models of 
TH-MYCN neuroblastoma, where PI3K inhibition with LY294002 and the dual PI3K-mTOR inhibitor 
BEZ235 showed antitumour effects via increase of MYCN phosphorylation and proteosomal 
degradation [25]. 
Moreover, Otto et al. have shown that Aurora kinase A is a synthetic lethal gene to MYCN 
(synthetic lethality arises when a combination of mutations in two or more genes leads to cell 
death), and proved that enzyme inhibition stabilizes MYCN [26]. The Aurora kinase A inhibitor 
MLN8237 showed very good anti-neuroblastoma responses in mouse xenografts when tested by 
the National Cancer Institute-driven Pediatric Preclinical Testing Program (PPTP), although it is not 
known whether this is dependent on destabilisation of MYCN [27]. Several clinical trials are 
evaluating Aurora kinase inhibition in children and there is major interest for its role in 
neuroblastoma, especially MYCN amplified disease [28-29]. 
Also Molenaar et al. have demonstrated that CDK2 is synthetically lethal to neuroblastoma cells 
with MYCN amplification and increased protein expression [30]. Additionally, treatment with 
roscovitine (CYC202, a CDK2, 7 and 9 inhibitor) induced MYCN-dependent apoptosis. 
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2. The PI3K/AKT signalling pathway 
The phosphoinositide 3-kinases are enzymes that are primarily involved in the phosphorylation of 
membrane inositol lipids, mediating cellular signal transduction. Although PI3K was originally 
characterized two decades ago through its binding to oncogenes and activated receptor tyrosine 
kinases (RTKs) its association with human cancer was not established until the late 1990s, when it 
was shown that the tumour suppressor PTEN acts as a phosphatase that is specific for the lipid 
products of PI3K [31]. 
PI3Ks are divided into three classes according to their structural characteristics and substrate 
specificity. Of these, the most commonly studied are the class I enzymes that are activated directly 
by cell surface receptors. Class I PI3Ks are further divided into class IA enzymes, which are 
activated by RTKs, G protein coupled receptors (GPCR) and certain oncogenes such as the small 
G protein RAS, and class IB enzymes, which are regulated exclusively by GPCRs [31-33]. 
The class I PI3Ks —p110α (also known as PIK3CA), p110β (also known as PIK3CB), p110γ (also 
known as PIK3CG) and p110δ (also known as PIK3CD) — are best understood, although much 
remains to be learnt about their coupling to upstream signals and their relative functional output. 
Class II and III PI3Ks remain enigmatic, with ill-defined roles in signal transduction.  
Both RTKs and non-RTKs result in the activation of PI3K, which generates the second messenger 
Phosphatidylinositol (3, 4, 5)-trisphosphate (PIP3) from Phosphatidylinositol (4, 5)-bisphosphate 
(PIP2). This recruits pleckstrin homology (PH) domain- containing proteins to the cell membrane, 
including the AKT/PKB kinases, driving their conformational change and resulting in their 
phosphorylation by the constitutively active phosphoinositide-dependent kinase 1 (PDK1) at 
Threonine 308 and by PDK2 [mammalian target of rapamycin complex 2 (mTORC2)] at Serine 473 
(Figure 1). Activated AKT translocates to the cytoplasm and nucleus and activates downstream 
targets involved in survival, proliferation, cell cycle progression, growth, migration, and 
angiogenesis. AKT is negatively regulated by the tumour suppressor PTEN (phosphatase and 
tensin homolog deleted on chromosome 10), which dephosphorylates PIP3. AKT mediates the 
phosphorylation and activation of mTOR complex 1 (mTORC1), a serine/threonine kinase that 
plays critical roles in the regulation of protein translation and synthesis, angiogenesis and cell cycle 
progression [31-33].  
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Figure 1, Schematic representation of the phosphorylation cascade through the PI3K/AKT/mTOR pathway. 
Arrows ending with a square represent inhibitory pathways. Adapted from [31, 34] 
 
PI3K pathway activation by genetic mutation or amplification (for example PIK3CA mutations in 
breast cancer) plays a particularly relevant role in several adult malignancies such as glioblastoma, 
breast or prostate cancer [35].  
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3. The PI3K/AKT signalling pathway is activated in neuroblastoma 
The PI3K pathway is activated in a variety of human cancers through multiple mechanisms. PI3K 
plays a crucial role in effecting alterations in a broad range of cellular functions in response to 
extracellular signals. The pathway is constitutively activated by the loss of the tumour suppressor 
PTEN, a phosphatase that counteracts the kinase activity of PI3K in many tumour types [36-37]. A 
key downstream effector of PI3K is the serine-threonine kinase AKT which, in response to PI3K 
activation, phosphorylates and regulates the activity of a number of targets including kinases, 
transcription factors and other regulatory molecules. AKT is a downstream target for PI3K and is 
overexpressed in a variety of cancers [38-40].  
Activating mutations within the PI3K subunit p110  (PIK3CA) have been detected in many human 
cancers with the majority of mutations located in the kinase domain [41-44]. These activating 
mutations promote growth and invasion in cancer cells, which is abrogated by PI3K inhibition [45].  
PI3K pathway activation in response to activation of receptor tyrosine kinases such as EGFR, 
PDGFR and IGF-1R is more common, and increased AKT phosphorylation is independently 
predictive of poor clinical outcome in neuroblastoma and glioma [46-47].  
Opel et al. found increased AKT, S6 and ERK phosphorylation in neuroblastoma samples. AKT 
activation also correlated with MYCN amplification. They also found how IGF-1R pathway 
activation is related to tumour apoptosis in a PI3K-dependent manner [47]. Additionally, it has been 
shown that dual inhibition of IGF-1R and mTOR results in decreased MYCN protein expression, 
increased MYCN phosphorylation and induced apoptosis in neuroblastoma cell lines [48].  
Activating mutations in PI3K pathway components promote growth and invasion of cancer cells, 
and can be abrogated by PI3K inhibitors. For paediatric solid tumours, inhibition of the PI3K 
pathway is a promising novel therapeutic approach likely to be efficacious in three groups of 
paediatric cancers:  
- Tumours with PI3K pathway activating mutations (PI3KCA, AKT, PTEN) such as 
medulloblastoma and malignant gliomas.  
- Tumours with persistent pathway activation (increased AKT phosphorylation), including 
malignant central nervous system (CNS) (glioma, medulloblastoma) and non-CNS 
(neuroblastoma) tumours.  
- Tumours with MYCN gene amplification (since the MYCN protein is a direct PI3K target) 
including neuroblastoma, medulloblastoma and alveolar rhabdomyosarcoma. 
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Tumour mass in MYCN-transgenic animals treated with the pure PI3K inhibitor LY294002 was 
decreased significantly in comparison with vehicle controls. This compound reduced the 
accumulation of viable cells in both MYCN amplified and non amplified cell lines, although this 
effect was less prominent in the latter group [24].  
In TH-MYCN murine neuroblastoma models, treatment with the dual PI3K-mTOR inhibitor BEZ235 
[49] inhibited tumour growth and the PI3K/AKT/mTOR signalling pathway, reduced neuroblastoma 
cell growth in vitro and destabilised wild-type MYCN and attenuated PI3K/mTOR signalling in vitro. 
Similar effects were found when the mTORC inhibitor AZD8055 was tested [50]. 
Pharmacologic inhibition of the PI3K/AKT/mTOR pathway is a promising target in adult and 
paediatric tumours, including neuroblastoma. Pharmacologically viable PI3K, AKT or mTORC 
inhibitors are currently completing phase I evaluation in adults without significant toxicity [51-52], 
and trials of those compounds in paediatric patients are under planning. 
Potent and isoform-selective PI3K inhibitors with improved pharmacologic properties are now 
entering clinical trials [53]. Phase I/II studies of pure PI3K (GDC0941, XL147), dual PI3K/mTOR 
(BEZ235, BGT226, GDC0980), AKT (MK2206, perifosine) and mTORC1 and 2 (OSI027, AZD2014, 
AZD8055) inhibitors are ongoing in adults [35]. Preliminary results from these studies suggest that 
these agents are well tolerated and have favourable pharmacokinetic/pharmacodynamic (PK-PD) 
profiles. Emerging data indicate that isoform selectivity may be important to maximize therapeutic 
benefit and minimize toxicity, although concerns remain about tumour cell redundancy between 
different isoforms.  
Several AKT inhibitors have been tested in paediatric tumour models showing anti-tumour activity. 
The evaluation of GSK690693 by the Pediatric Preclinical Testing Program showed survival 
improvements in osteosarcoma and glioblastoma [54]. Perifosine was shown to be active in 
neuroblastoma [55], glioma [56], medulloblastoma [57] or sarcomas [58]. 
Proof of principle that the PI3K pathway can be successfully targeted for clinical use in cancer has 
been demonstrated by the development of rapamycin analogs (temsirolimus, everolimus, 
ridaforolimus) that inhibit the mTORC1 kinase. However, preliminary results to date have been 
disappointing when these analogs have been administered as single agents [59-60]. Superior 
single-agent activity may potentially be seen with dual mTORC1/mTORC2 ATP-competitive kinase 
inhibitors, which are currently in clinical development (OSI027, AZD8055, AZD2014). These 
broader spectrum inhibitors may, however, be more toxic. mTORC1/mTORC2 inhibitors should, 
nonetheless, abrogate the reported negative-feedback loops associated with rapamycin analog 
administration, resulting in activation of upstream targets such as IGF-1R and phospho-AKT [61]. 
Other investigators have found benefit of mTOR inhibition via MYCN degradation using rapamycin 
for the treatment of neuroblastoma [62] or for the combinations with other agents such as IGF-1R 
inhibitors [48, 63-64] 
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Currently, early clinical trials are beginning to evaluate targeted therapies in children with 
neuroblastoma, including ALK inhibitors [65], Aurora kinase inhibitors [29, 66-67] or IGF-1R 
inhibitors [68]. It is envisioned that within the next decade, a number of potentially relevant drugs to 
neuroblastoma will be tested in the paediatric population, including PI3K, AKT, mTORC, CDK 
inhibitors and other involved signalling pathways. Pharmacodynamic biomarkers will be needed in 
order to select most promising agents and classes to be taken forward into large phase III clinical 
trials and eventually into the clinic.  
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4. Development of pharmacodynamic (PD) biomarkers 
Biomarkers have been defined as biological characteristics that can be objectively measured and 
evaluated as an indicator of normal biological or pathological processes, or pharmacological 
responses to a therapeutic intervention [69]. 
 
4.1 Types and steps of development 
Three main types of biomarkers have been defined [70]: 
- Prognostic biomarkers, give information on prognostic features helping to distinguish 
between cases with good or poor outcome (e.g. patients with higher level of circulating 
tumour cells at diagnosis have worse survival than those with no circulating tumour cells 
[71].  
- Predictive biomarkers, assess the probability that a patient will benefit from a particular 
treatment (e.g. patients with HER2-positive breast cancer will benefit from treatment with 
the anti-HER2 monoclonal antibody transtuzumab) [72-73]. 
- Pharmacological/PD biomarkers, measure effects of the drug on the tumour e.g. the AKT 
inhibitor MK2206 given at the recommended phase 2 dose inhibits effectively AKT in 
tumour cells and other surrogate biomarkers [74]. PD biomarkers are of major value in 
making ―go-no go‖ decisions and assess performance of new drugs.  
Four steps are required during biomarker development [75]: 
- Discovery. In this phase aspects of tumour biology are shown to correlate with clinical 
endpoints such as survival. Often ‗omics‘ platforms that analyse a large number of 
biomarkers are used to generate hypothesis which are then refined in further developments. 
- Validation. This phase is required to determine that the assay is fit-for-purpose for 
objective measurement. Reproducibility, accuracy, precision and recovery have to be 
determined.  
- Qualification. Correlation of biomarkers with clinical endpoint. Sensitivity and specificity of 
the specific assay are determined. 
- Implementation. Implementation in the clinic to help clinical decision taking.  
 
4.2 Relevance of biomarkers 
The use of pharmacodynamic profiling is essential for the optimal clinical development of targeted 
anti-cancer agents. These assays are key to demonstrate proof-of-principle for target modulation, 
to establish optimal drug dosing and schedule, to maximise the extent and duration of target 
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blockade and to evaluate the downstream biological effects of target modulation on cancer cell 
proliferation and survival [73]. Several PD biomarkers have been used in adult early clinical trials 
and need to be adapted to the paediatric population. Additionally, prognostic and predictive 
biomarkers are needed in children in order to improve risk stratification and to select patients that 
will benefit most from targeted therapies (i.e. enrich for anaplastic lymphoma kinase (ALK) gene -
mutated neuroblastomas in a clinical trial of an ALK inhibitor). So far, early clinical trials in children 
have lacked PD biomarkers to demonstrate proof-of-principle for target modulation, improve drug 
dosing and schedule, or assess downstream biological effects of target modulation and in 
summary, help in the ―go-no go‖ decisions to larger phase III studies.  
The objective of the Royal Marsden Hospital – Institute of Cancer Research (RMH/ICR) Paediatric 
Drug Development Program is to integrate biomarkers in early clinical trials to provide prognostic 
stratification, selection of appropriate therapy by predictive biomarkers and to measure the effect 
on pathway targeting by PD biomarkers [76-78]. 
4.3 Sources of biomarkers 
Tumour material is the best tissue in which to develop new biomarkers. However, when translated 
into human studies, this implies significant logistic and sometimes ethical difficulties, as tumour 
tissue is often difficult to obtain and often repeated samples are required. This is a key difficulty in 
the case of childhood malignancies where most tumours are not easily accessible for biopsy and 
biopsy requires an anaesthetic procedure.  
To date, some PD biomarkers have been established in adults at the ICR using surrogate tissues 
such as peripheral blood mononuclear cells (PBMC), plucked hair follicles or skin fibroblasts for 
phase I trials.  
Due to the specific characteristics of neuroblastoma, especially in the relapsed setting, several 
sources of tumour material or surrogate tissues can be explored. Primary tumours mostly arise in 
the suprarenal area or retroperitoneal cavity and therefore, biopsy can be risky and challenging. 
Most frequent sites of metastases are skeleton and bone marrow and less so lungs or central 
nervous system (CNS) [2].  
 
4.4 Surrogate biomarkers 
Increase in AKT phosphorylation in PBMC or PRP was shown after treatment with the AKT 
inhibitor MK2206 [52, 79]. Several pharmacodynamic biomarkers of the PI3K/AKT/mTOR pathway 
have been used in different adult phase I studies including IGF-1R, EGFR, IRS-1, p-AKT, p-MAPK, 
p-S6 and p-4EBP1 [80-82]. 
A pharmacological biomarker assay has been developed at ICR to measure PI3K pathway 
inhibition, using Meso Scale Discovery (MSD®) technology, in adult tumour material or surrogate 
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PRP samples in accordance with Good Clinical Laboratory Practice (GCLP) on adult trials at The 
Royal Marsden Hospital (RMH) [83-85]. Those biomarkers have not been used in paediatric clinical 
trials and its validity has still to be proven.  
 
4.5 Bone marrow samples to develop PD biomarkers 
Given that 80% of patients with high-risk neuroblastoma have tumour bone marrow involvement [5, 
86], the isolation of tumour material from bone marrow samples, which are otherwise frequently 
obtained for clinical purposes, is a feasible approach. This degree of involvement ranges from 10 
to 99% of nucleated cells and bone marrow aspiration and trephine biopsies are used as part of 
routine clinical assessments of cases with metastatic disease. 
Several FISH (fluorescence in situ hybridisation), RT-PCR (real time polymerase chain reaction) or 
protein phosphorylation assays of different tumour pathways such as PI3K/AKT/mTOR, IGF-1R, 
EGFR, PDGFR or Aurora Kinase among others to be used in early clinical trials of anticancer 
drugs require high purity of tumour cells. Therefore, a procedure to isolate and enrich 
neuroblastoma cells from bone marrow samples of children with neuroblastoma is needed for this 
purpose. 
Bone marrow-derived neuroblastoma cells have been used by the Ghent group to perform 
genomic analyses. In a very preliminary report, Vandewoestyne et al. were able to use bone 
marrow neuroblasts for FISH and array CGH (comparative genomic hybridisation) assays, showing 
similar array profiles of bone marrow samples compared to primary tumours [87]. Bone marrow 
samples have also been used to detect neuroblastoma mRNA and this assay is widely used 
across Europe [88].  
 
4.6 Use of biomarkers in paediatric clinical trials 
A limited number of phase I/II studies in children have included predictive biomarkers to select 
patients who would most benefit from targeted therapy. 
A study of the PDGFR inhibitor imatinib in children with solid tumours used target expression as a 
predictive biomarker and included only patients with PDGFR or c-Kit expression. No correlation 
with clinical response or outcome was found [89]. 
Several studies of drugs targeting EGFR have also reported results on target expression in tumour 
samples or mutation analysis. A phase I of erlotinib in children found no correlation between 
markers of PI3K/AKT pathway activation, including mutational analysis for PTEN and PIK3CA and 
response to the current therapy [90]. Likewise, a phase I study of erlotinib with temozolomide for 
children with solid tumours or a phase I study of cetuximab plus irinotecan in children found 
pathway activation but no clinical correlation [91-92]. Those studies aimed to identify those patients 
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that would most benefit from EGFR inhibition based on their EGFR mutational status or pathway 
activation in samples which were mostly retrospectively collected from diagnosis. However, it was 
not proved whether the pathway was pharmacologically inhibited at the given doses.  
More recently, early clinical trials have also incorporated PD biomarkers. Two studies testing 
bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), in 
children have prospectively investigated PD biomarkers in blood or with new imaging modalities. In 
the first phase I study, circulating markers including circulating endothelial cells (CEC), circulating 
endothelial progenitor (CEP) cells and other soluble factors such as VEGF or b-FGF (fibroblast 
growth factor) showed significant inter-patient variability and no correlation was observed with 
clinical benefit [93]. However, a second study testing bevacizumab added to irinotecan in children 
with recurrent malignant glioma or diffuse brainstem glioma found target inhibition showed a 
reduction in phospho-VEGFR2 levels after treatment. Assessment of VEGFR phosphorylation 
status in PBMCs showed decreased levels of phosphorylation and target inhibition in a number of 
patients. However, despite proving effective VEGF inhibition, the trial failed to show any clinical 
benefit for the patients [94]. 
A recent paediatric phase I study of the mTOR inhibitor temsirolimus (CCI779) measured p-S6, p-
AKT and p-4EBP1 by Western blot in PBMC´s at different time points during therapy [59]. Despite 
marked inter-patient variability, reductions in all three phospho-proteins were detectable from two 
hours after temsirolimus dosing and those reductions were more profound from course two 
onwards. No correlation with PK or patient benefit was found.  
PD biomarkers have shown target inhibition and have aided in the dose selection in a phase I trial 
of vorinostat, an HDAC inhibitor. In this study, accumulation of acetyl H3 histones in PBMCs was 
detected in patients receiving the highest vorinostat dosages and particularly in patients treated 
with the higher dose level in whom accumulation of acetyl-H3 persisted for 24 hours. Evidence of a 
more transient (6 hours) PBMC acetyl H3 accumulation was observed in patients receiving 
intermediate doses, and no accumulation was found in the lower dose levels [95].  
 
4.7 Good Clinical Practice (GCP) and Good Clinical Laboratory Practice (GCLP) standards 
Good Clinical Practice is a set of internationally recognised ethical and scientific quality 
requirements which must be observed for designing, conducting, recording and reporting clinical 
trials that involve the participation of human subjects [96]. 
Compliance with this good practice provides assurance that the rights, safety and well-being of trial 
subjects are protected, and that the results of the clinical trials are credible and accurate. 
The conduct of clinical trials on medicinal products for human use is regulated by the European 
Clinical Trial Directive 2001/20/EC [97]. The principles of Good Clinical Practice to be followed for 
the conduct of clinical trials in human subjects are outlined in articles 2 to 5 in the EU Directive 
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2005/28/EC [98]. There is now extensive regulation and guidance for research assays to be used 
in clinical trials including recommendations from the European Medicines Agency (EMA) for 
research involving children [99].  
Good Clinical Laboratory Practice (GCLP) provides a bridge between GCP and GLP (Good 
Laboratory Practice). It provides a framework to organisations on facilities, systems and procedure 
to ensure the reliability, quality and integrity of the work and results satisfy GCP expectations [100]. 
It applies to all samples generated during the conduct of a clinical trial and includes  
 Organisation and Personnel 
 Facilities 
 Equipment, materials and reagents 
 Standard Operating Procedures (SOPs) 
 Planning, conduct and reporting 
 Quality Control and Quality audits 
 Retention of study records and reports. 
Those principles were established by the British Association on Research Quality Assurance 
(BARQA) in order to ensure the compliance with GCP and GLP in clinical trials conducted in the 
United Kingdom [100]. 
The Clinical PD Biomarker Group Laboratory at the ICR is a laboratory specifically designed to 
adhere to GCP and GCLP in order to provide the highest standard for pharmacokinetic and 
pharmacodynamic analyses in phase I/II clinical trials of targeted agents carried out at RMH/ICR. 
In order to facilitate the implementation of all assays developed within this study, all laboratory 
work was performed at the Clinical PD Biomarker Group Laboratory at the ICR following strict GCP 
and GCLP standards.  
 
4.8 Development of PD biomarkers of the PI3K pathway in neuroblastoma 
The main hypothesis of the Neuroblastoma Drug Development Team at the ICR led by Dr Chesler 
is that drugs targeting the PI3K/mTOR pathway will have a specific benefit in children with MYCN 
amplified and expressing neuroblastoma by destabilisation of MYCN protein. The upcoming phase 
I clinical trials of drugs targeting the PI3K/AKT/mTOR pathway need to include pharmacodynamic 
biomarkers determining total and phospho protein signals targeted by the new agents, the effects 
upstream and downstream the pathway and functional imaging to evaluate effects on tumour 
vasculature and perfusion. 
Pharmacodynamic biomarkers in neuroblastoma, Lucas Moreno, January 2012 
33 
If these biomarkers are not implemented, the drug development process for neuroblastoma and 
other high risk childhood cancers will be empiric and will not be led by scientific hypotheses. There 
will be substantial risks of withdrawing potentially useful agents because the schedule does not 
achieve sustained target inhibition, only a small proportion of patients benefit from the drug and 
allowing ineffective drugs progress into phase II/III trials, implying that a large number of children 
with advanced cancers will receive ineffective agents.  
The incorporation of scientifically and analytically validated biomarkers into rationally designed 
hypothesis-testing clinical trials offers a promising way forward to increasing the odds for 
successful and efficient transition of a compounds through the drug development pipeline [77]. 
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1. Neuroblastoma 
1.1 El neuroblastoma de alto riesgo (metastásico o MYCN-amplificado) es un cáncer infantil 
de mal pronóstico 
El neuroblastoma es un tumor derivado del sistema nervioso simpático y constituye el tumor sólido 
más frecuente en la edad pediátrica. El patólogo alemán R.L.K. Virchow lo describió por primera 
vez en 1864 [1]. El espectro clínico del neuroblastoma es extremadamente amplio, desde tumores 
que regresan espontáneamente o maduran a ganglioneuroma en formas localizadas y niños 
menores de 18 meses [2-4] hasta formas metastásicas y MYCN amplificadas que si bien 
inicialmente son quimiosensibles, acaban desarrollando quimio-resistencia [5-6]. 
Aunque el pronóstico del cáncer infantil ha mejorado significativamente durante las pasadas 
décadas, todavía es la principal cause de muerte por enfermedad en la edad pediátrica en países 
desarrollados y un 25% de los niños con cáncer fallecen por la enfermedad. Según los datos 
recogidos por el registro epidemiológico EUROCARE, hay aproximadamente 400 casos de 
neuroblastoma al año en Europa Occidental [7]. 
Alrededor de la mitad de los casos se presentan en estadios avanzados o tienen factores 
biológicos adversos. Estos pacientes presentan una alta tasa de recaídas y en conjunto 
representan el 15% de las muertes por cáncer infantil [8-9].  
El neuroblastoma de alto riesgo está formado por dos grupos: aquellos pacientes con enfermedad 
metastásica al diagnostico o aquellos cuyos tumores presentan amplificación del oncogén MYCN 
[10]. A pesar de un tratamiento de primera línea multimodal e intensivo, consistente en 
quimioterapia, cirugía, megaterapia con transplante autólogo de progenitores hematopoyéticos, 
radioterapia al lecho tumoral primario y tratamiento diferenciador más del 70% de los pacientes 
sufren recaídas [6]. Recientemente, la adición de inmunoterapia para tratar la enfermedad residual 
ha demostrado incrementar en un 20% la supervivencia libre de eventos [11]. El pronóstico tras la 
recaída es extremadamente pobre para los pacientes que han recibido tratamiento con 
megaterapia y transplante autólogo [13]. Estos pacientes que ya han agotado el tratamiento 
convencional definen una cohorte en la que el tratamiento de segunda línea obtiene una 
supervivencia global menor del 8%. Por tanto hay una necesidad no satisfecha de desarrollar 
nuevos medicamentos contra el neuroblastoma de alto riesgo. 
 
1.2 Amplificacion de MYCN en el neuroblastoma 
La amplificación del oncogén MYCN es el marcador genómico más relevante de los disponibles 
para un tratamiento estratificado por categorías de riesgo. En análisis multivariante ha demostrado 
identificar pacientes con mal pronóstico [17-18] independientemente de su estadio. La 
amplificación del oncogén MYCN, localizada en el cromosoma 2p24fue inicialmente descrita por 
Scwab y col. en 1983 [16] y se encuentra en aproximadamente un 25% de los casos. Dicha 
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amplificación del oncogén MYCN se encuentra además en otros tumores incluyendo carcinoma 
microcítico de pulmón (7%), rabdomiosarcoma alveolar (60%) y retinoblastoma (20%) [19]. 
Aberraciones en la expresión de miembros de la familia de genes MYC (c-myc y MYCN) 
contribuyen asimismo a otros canceres del adulto (linfoma de Burkitt y linfoma no Hodgkin) y de la 
edad pediátrica. 
Normalmente la expresión de MYCN está restringida a estadios iniciales del desarrollo 
embrionario. La deleción homocigota de MYC o MYCN en ratones resulta en letalidad de los 
embriones, en tanto que modelos transgénicos con sobreexpresión de MYC o MYCN desarrollan 
una variedad de tumores, lo que sugiere que dicho oncogén juega un papel crucial tanto en el 
desarrollo embrionario como en la biología tumoral [20]. Actualmente, dichos modelos 
transgénicos recapitulan la biología tumoral del neuroblastoma humano presentando un perfil 
genético similar [20]. Los miembros de la familia MYC son factores de transcripción, proteínas que 
activan la transcripción de determinados genes [19, 21]. 
 
1.3 MYCN como diana terapéutica 
Debido a su papel central en la aparición del neuroblastoma y el potente estimulo oncogénico que 
supone, MYCN es una diana interesante para el desarrollo de nuevos fármacos antitumorales.  
La amplificación de MYCN se traduce en niveles altos de expresión de la proteína MYCN 
derivando en efectos en la proliferación celular, angiogénesis, diferenciación y potencial invasivo. 
Por tanto, MYCN y MYCN son dianas terapéuticas atractivas para los tumores dependientes de 
MYCN. Aunque todavía no se ha establecido si un inhibidor especifico de MYCN seria efectivo, 
distintas estrategias terapéuticas que van desde el nivel génico a proteico están en estudio y los 
resultados preliminares son prometedores [21]. 
En la década de los 90 varios tratamientos dirigidos contra el oncogén MYCN con DNA antisentido 
se llevaron a cabo en modelos preclínicos aunque esta estrategia terapéutica no fue 
efectivamente trasladada a la clínica [22-23]. 
Varios genes candidatos que son regulados directa o indirectamente por MYCN pueden ser 
dianas terapéuticas con nuevas moléculas que actualmente están en desarrollo preclínico o clínico, 
principalmente MDM2 (vía de señalización de p53), DKK3 (inhibidores de WNT), SKP2 
(inhibidores del proteosoma) y Aurora Kinasa A [21]. 
Recientemente, se ha demostrado que la fosforilación de la proteína MYCN produce 
desestabilización y degradación en el proteosoma de la proteína, frenando así sus efectos 
deletéreos. Terapias moleculares contra distintas vías de señalización como inhibidores de 
PI3K/AKT/mTOR, CDK o Aurora Kinasas son capaces de fosforilar MYCN y este es un área 
donde los esfuerzos investigadores se han intensificado. El grupo de Chesler y col. (Universidad 
de San Francisco, USA) demostró como la inhibición farmacológica de PI3K en modelos 
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transgénicos TH-MYCN producía un descenso en los niveles de proteína MYCN frenando el 
crecimiento tumoral [24]. Este grupo ha demostrado que la inhibición selectiva de PI3K con 
LY294002 bloquea MYCN a nivel post-transcripcional disminuyendo los niveles de proteína MYCN 
vía activación de GSK3β que fosforila MYCN y desestabiliza la proteína. 
Este grupo planteo la hipótesis de que los neuroblastomas con amplificación de MYCN son 
―adictos‖ a la oncoproteína MYCN y que por tanto, el bloqueo farmacológico de esta vía de 
señalización resultaría en excelentes efectos antitumorales [24]. Esta hipótesis se ha demostrado 
en los modelos murinos genéticamente modificados TH-MYCN de neuroblastoma donde la 
inhibición de PI3K con LY294002, con el inhibidor dual de PI3K/mTOR BEZ235 y el inhibidor de 
mTORC AZD8055 demostró excelentes resultados mediante el aumento de la fosforilación de 
MYCN resultando en degradación proteosomal [25, 50]. 
Además, Otto y col. han demostrado como Aurora kinasa A es un gen sintéticamente letal para 
MYCN y demostrado como la inhibición de dicha enzima estabiliza MYCN [26]. El tratamiento de 
modelos animales de neuroblastoma (xenoinjertos murinos) con el inhibidor de Aurora kinasas 
MLN8237 fue muy efectivo en el análisis realizado por el grupo colaborativo PPTP (Pediatric 
Preclinical Testing Program) en Estados Unidos, aunque este grupo no demostró si el efecto 
beneficioso se produjo mediante la desestabilización de MYCN [27]. Varios ensayos clínicos fase 
I/II están evaluando el uso de inhibidores de Aurora kinasas en la población infantil y hay un gran 
interés en el tratamiento del neuroblastoma, especialmente en los casos de amplificación de 
MYCN [28-29]. 
Análogamente, Molenaar y col. han demostrado que CDK2 es sintéticamente letal para las células 
de neuroblastoma con amplificación y sobreexpresión de MYCN. El tratamiento con roscovitina 
(un inhibidor de CDK en desarrollo preclínico) indujo apoptosis dependiente de MYCN [30]. 
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2. La vía de señalización PI3K/AKT 
La familia de PI3-kinasa (PI3K) está principalmente relacionada con la fosforilación de inositol en 
la membrana celular, mediando vías de señalización intracelular. Aunque PI3K fue inicialmente 
caracterizada hace tres décadas mediante su afinidad por oncogenes y receptores de tirosín-
kinasas, su relación con el cáncer no se estableció hasta finales de los 90 cuando se demostró 
que el gen supresor de tumores PTEN actúa como una fosfatasa específica para los productos 
lipídicos de PI3K [31]. 
Las PI3-kinasas se dividen en tres clases de acuerdo con sus características estructurales y 
especificidad por sustratos. De estas, la más conocida es la clase I de enzimas que son activadas 
directamente por receptores de la superficie celular. Las kinasas de clase I se dividen en: IA, que 
son activadas por receptores tirosín-kinasas, receptores acoplados a proteína G y determinados 
oncogenes como la proteína G Ras y IB que están reguladas exclusivamente por receptores 
acoplados a proteína G [31-33]. 
Las kinasas de clase I más conocidas son p110α (también conocida como PIK3CA), p110 β 
(también conocida como PIK3CB), p110γ (también llamada PIK3CG) y p110δ (también llamada 
PIK3CD). Dichas kinasas son las más estudiadas, aunque todavía quedan por esclarecer los 
mecanismos de transmisión de las señales y su compleja función. Las kinasas de clase II 
continúan siendo enigmáticas con roles poco definidos en la transducción de señales. La 
importancia fisiológica de VPS34 (proteína vacuolar de caracterización 34, también conocida 
como PIK3C3) es desconocida.   
Tanto receptores de tirosín-kinasa como otros receptores activan PI3K lo que genera el segundo 
mensajero fosfatidilinosidil-(3,5) trifosfato a partir de fosfatidilinosidil (4,5) bifosfato. Esto genera el 
reclutamiento de proteínas a la membrana celular incluyendo las kinasas AKT/PKB produciendo 
un cambio conformacional que resulta en su fosforilación por la kinasa PDK1 (kinasa 
fosfatidilinositol dependiente) en la Treonina 308 y por PDK2 (o mTORC2, [mammalian target of 
rapamycin complex 2]) en la Serina 473. La proteína AKT activada se transloca al citoplasma y el 
núcleo y activa dianas relacionadas con la supervivencia celular, proliferación, progresión del ciclo 
celular, crecimiento, migración y angiogénesis. AKT es regulada negativamente por el supresor de 
tumores PTEN (phosphatase and tensin homolog) situado en el cromosoma 10, que desfosforila al 
inositol tri-fosfato. AKT media la fosforilación y activación del complejo mTOR1 (mTORC1), una 
serin-treonín kinasa que juega papeles críticos en la regulación de la traducción y síntesis proteica, 
angiogénesis y progresión del ciclo celular [31-33]. 
La activación de la vía de señalización celular PI3K mediante mutación genética o amplificación 
juega un papel especialmente relevante en diversos canceres del adulto, como glioblastoma 
multiforme, cáncer de mama o próstata [35]. 
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3. La vía de señalización PI3K/AKT esta activada en neuroblastoma 
La cascada de PI3K esta activada en diversos canceres humanos mediante múltiples mecanismos. 
Dicha cascada juega un papel crucial en una amplia variedad de funciones celulares en respuesta 
a estímulos extracelulares. La vía es constitucionalmente activada por la pérdida del supresor de 
tumores PTEN, una fosfatasa que frena la actividad kinasa de PI3K en muchos tipos de tumores 
[36]. El principal efector de PI3K es la Serina-Treonina kinasa AKT que en respuesta a la 
activación de PI3K fosforila y regula la actividad de varias proteínas incluyendo kinasas, factores 
de transcripción y otras moléculas reguladoras. Asimismo, AKT esta sobreexpresada en diversos 
canceres humanos [38-40].  
Mutaciones activadoras de la subunidad p110  (PIK3CA) se han detectado en canceres humanos. 
La mayoría de ellas situadas en el dominio kinasa [42-44]. Estas mutaciones que promueven el 
crecimiento y la invasión de las células tumorales pueden ser contrarrestadas mediante la 
inhibición farmacológica de PI3K [101]. 
La activación de la cascada de PI3K en respuesta a la activación de receptores de tirosín-kinasas 
como EGFR (receptor de factor de crecimiento epidérmico), PDGFR (receptor de factor de 
crecimiento derivado de plaquetas) e IGF-1R (receptor de factor de crecimiento relacionado con 
insulina) ocurre con frecuencia. Varios autores han demostrado que un aumento de AKT 
fosforilada es predictor independiente de mal pronóstico en neuroblastoma y glioma [47]. 
Opel y col. demostraron la existencia de hiperfosforilación de AKT, S6 y ERK en muestras de 
neuroblastoma humano, así como una correlación entre la activación de AKT y la amplificación de 
MYCN. También se demostró que la activación de IGF-1R deriva en apoptosis tumoral de manera 
dependiente de la vía de PI3K [47]. Asimismo, otros autores han demostrado que la inhibición 
simultanea de IGF-1R y mTOR resulta en una reducción de la expresión de MYCN, aumento de la 
fosforilación de MYCN y la inducción de apoptosis en líneas celulares de neuroblastoma [48, 63]. 
Mutaciones activadoras de componentes de PI3K generan el crecimiento y la invasión de células 
tumorales que pueden ser suprimidas mediante inhibición farmacológica. En el caso de los 
tumores sólidos pediátricos, la inhibición de PI3K es una diana terapéutica prometedora para tres 
grupos de canceres pediátricos: 
- Tumores con mutaciones activadoras (PIK3CA, AKT, PTEN) 
- Tumores con activación de la vía de señalización (hiperfosforilación de AKT), incluyendo 
tumores cerebrales malignos como glioma de alto grado o meduloblastoma y 
extracraneales como el neuroblastoma.  
- Tumores con amplificación del oncogén MYCN, dado que la proteína MYCN es una diana 
directa de PI3K, incluyendo neuroblastoma, meduloblastoma y rabdomiosarcoma alveolar. 
El tratamiento de ratones transgénicos con neuroblastoma (TH-MYCN) con el inhibidor de PI3K 
LY294002 produjo una reducción significativa de la masa tumoral en comparación con animales 
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tratados con placebo. Este compuesto redujo la acumulación de células viables en líneas celulares 
con y sin amplificación de MYCN, aunque de manera más prominente en el primer grupo [24]. 
Análogamente, el mismo modelo murino tratado con el inhibidor dual de PI3K y mTOR BEZ235 
produjo inhibición del crecimiento tumoral mediante inhibición de la cascada de señalización de 
PI3K/AKT/mTOR, reducción del crecimiento celular in vitro, desestabilización de la proteína MYCN 
in vitro, bloqueo de la activación de la cascada PI3K producida mediante factores de crecimiento, 
así como el bloqueo del componente mTOR de la vía de señalización en células Kelly in vitro 
resultando en la desestabilización de MYCN y perdida de la viabilidad celular [25]. 
La inhibición farmacológica de PI3K/AKT/mTOR es una diana altamente interesante en oncología 
médica y pediátrica, incluyendo al neuroblastoma. Actualmente, existen múltiples inhibidores de 
PI3K o AKT en desarrollo clínico completando ensayos clínicos de fase I sin encontrar toxicidad 
significativa [51-52] y los ensayos clínicos pediátricos de dichos compuestos están en preparación. 
Actualmente múltiples ensayos clínicos fase I/II en adultos están abiertos evaluando inhibidores 
puros de PI3K (GDC0941, XL147), duales de PI3K y mTOR (BEZ235, BGT226, GDC0980), AKT 
(MK2206, Perifosine) y mTORC1 y 2 (OSI027, AZD2014, AZD8055). 
Inhibidores potentes y selectivos para isoformas especificas de PI3K con altas cualidades 
farmacológicas están siendo estudiados [53], p.ej. moléculas como XL147 (Exelixis), BEZ235 
(Novartis) y GDC0980 (Genentech). Los resultados preliminares de estos estudios sugieren que 
son fármacos bien tolerados con perfiles farmacocinéticos y farmacodinámicos favorables. Dichos 
resultados parecen sugerir que la selectividad frente a isoformas puede ser importante para 
maximizar el beneficio terapéutico y minimizar la toxicidad, aunque el riesgo de redundancia entre 
isoformas en estas cascadas de señalización podría derivar en falta de eficacia.  
Varios inhibidores de AKT han demostrado actividad antitumoral en modelos preclínicos de 
tumores infantiles. El análisis de GSK690693 por el grupo PPTP mostro mejorías en la 
supervivencia de xenoinjertos de glioblastoma y osteosarcoma [102]. Otro inhibidor de AKT, 
perifosina ha demostrado actividad antitumoral en estudios preclínicos en neuroblastoma [55], 
glioma [56], meduloblastoma [57] y sarcomas [58]. 
El uso de análogos de rapamicina (temsirolimus, everolimus) en canceres en adultos ha 
demostrado que es posible inhibir la cascada de PI3-kinasas mediante inhibición de la kinasa 
mTORC1 en humanos. Sin embargo, los resultados de estos agentes en monoterapia han sido 
subóptimos y se ha sugerido que la inhibición dual de mTORC1 y mTORC2 kinasas con 
inhibidores ATP-competitivos podría ser superior, aunque a riesgo de aumentar la toxicidad.  
Los inhibidores duales de mTORC1 y mTORC2 kinasas deberían ser capaces de evitar las 
señales de retroalimentación negativa que se producen con el uso de análogos de rapamicina que 
llevan a la activación de otras dianas celulares como IGF-1R y AKT.  
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Grupos de investigación en tumores pediátricos han demostrado que tanto la inhibición de mTOR 
con rapamicina en monoterapia como en combinación con inhibidores de IGF-1R producen 
efectos antitumorales mediante la degradación de MYCN en modelos de neuroblastoma [48, 62-
64].  
Actualmente, diversos ensayos clínicos pediátricos están evaluando terapias moleculares dirigidas, 
incluyendo inhibidores de ALK (COG-ADVL0912), de Aurora kinasas (COG-ADVL0921) o 
inhibidores de IGF-1R (R1507)[68]. Durante la próxima década, un gran número de fármacos 
biológicamente relevantes para el tratamiento del neuroblastoma serán evaluados en la población 
pediátrica incluyendo inhibidores de PI3K, AKT, CDK y otras cascadas de señalización. 
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4. Desarrollo de biomarcadores farmacodinámicos 
Los biomarcadores se definen como características biológicas que pueden ser medidas 
objetivamente y evaluadas como un indicador de un proceso biológico normal, de un proceso 
patológico o respuestas farmacológicas a una intervención terapéuticas [69]. 
 
4.1 Tipos y estadios del desarrollo de los biomarcadores 
Sawyers y col. han definido tres grandes grupos de biomarcadores: 
- Pronósticos, que dan información relativa a la evolución final del paciente, ayudando a 
diferenciar entre casos con buen y mal pronóstico. Por ejemplo, se ha demostrado que 
pacientes con mayor número de células tumorales circulantes en sangre al diagnostico 
tienen una peor supervivencia global que aquellos con menos células tumorales circulantes 
[71]. 
- Predictivos, que ayudan a determinar la probabilidad de que un paciente se beneficie de un 
tratamiento en particular. Por ejemplo, sólo los pacientes con cáncer de mama HER2 
positivo se benefician del tratamiento con el anticuerpo monoclonal anti-HER2 
transtuzumab [72-73]. 
- Farmacodinámicos o farmacológicos, que miden los efectos de los fármacos en el tumor. 
Están dirigidos a ayudar en la toma de decisiones acerca del desarrollo de nuevos 
fármacos y a evaluar sus efectos en las dianas terapéuticas. Por ejemplo, el inhibidor de 
AKT MK2206 a la dosis recomendada para ensayos fase II inhibe efectivamente AKT en 
células tumorales y otros biomarcadores indirectos [74]. 
Para desarrollar un biomarcador se requieren cuatro fases [75]: 
- Descubrimiento. En esta fase, aspectos de la biología tumoral se correlacionan con 
objetivos clínicos como por ejemplo supervivencia en el contexto de ‗estudios de 
investigación‘.  
- Validación. En esta fase se evalúa si la técnica utilizada es adecuada para medir el 
objetivo requerido. Se determinan reproducibilidad, precisión y exactitud.  
- Cualificación. Los biomarcadores se correlacionan con un objetivo clínico y se determinan 
sensibilidad y especificidad. 
- Implementación en la clínica para guiar la toma de decisiones clínicas. 
 
4.2 Relevancia de los biomarcadores 
El uso de biomarcadores farmacodinámicos es esencial para el desarrollo clínico óptimo de las 
nuevas terapias moleculares antitumorales. Estas técnicas son cruciales para demostrar que la 
diana terapéutica es efectivamente inhibida, establecer la dosis y el régimen adecuado, maximizar 
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la intensidad y la duración de la inhibición de la diana terapéutica y para evaluar los efectos 
biológicos más abajo en las cascadas de señalización, incluyendo los efectos en proliferación y 
supervivencia celular [73].  
Múltiples biomarcadores farmacodinámicos se están utilizando en los ensayos clínicos fase I y II 
en adultos y es preciso adaptar dichos biomarcadores para su uso en la población pediátrica. 
Asimismo, es necesario desarrollar mejores biomarcadores pronósticos y predictivos en niños 
para obtener el máximo beneficio de los tratamientos moleculares. Por ejemplo, seleccionar 
pacientes con neuroblastomas con mutaciones de ALK en los ensayos clínicos de inhibidores de 
ALK. Hasta la fecha, el uso de biomarcadores farmacodinámicos ha sido muy limitado en los 
ensayos clínicos pediátricos.  
El objetivo del programa de desarrollo de nuevos fármacos del Royal Marsden Hospital – Institute 
of Cancer Research es integrar los biomarcadores en ensayos clínicos fase I/II para mejorar la 
estratificación de pacientes, incluir biomarcadores de respuesta/predictivos y para medir el efecto 
de los antitumorales en las dianas terapéuticas [77]. 
 
4.3 Tejidos para biomarcadores 
Las muestras tumorales constituyen el mejor tejido para desarrollar nuevos biomarcadores. Sin 
embargo, cuando estas técnicas se trasladan al uso en humanos existen numerosas dificultades 
logísticas y éticas para obtener tejido tumoral, tanto porque es frecuentemente inaccesible como 
por la dificultad que representa la necesidad de obtener muestras tumorales seriadas. Esto es 
particularmente relevante en los canceres pediátricos dado que la mayoría de los tumores no son 
accesibles y se requerirían complejos procedimientos bajo anestesia general. 
En nuestra institución (ICR) se han desarrollado un número de biomarcadores indirectos que 
utilizan otros tejidos distintos del tumoral como células mononucleares de sangre periférica 
(PBMC), folículos pilosos o biopsias cutáneas que están siendo utilizados en múltiples ensayos 
clínicos. 
Dadas las características especificas del neuroblastoma, especialmente después de la primera 
recaída es preciso explorar otras fuentes de tejido para el desarrollo de biomarcadores. El tumor 
primario suele situarse en el área suprarrenal o la cavidad retroperitoneal y es, por tanto, de difícil 
acceso. Las localizaciones más frecuentes de metástasis son el esqueleto, la medula ósea y el 
hígado y con menos frecuencia en los pulmones o el sistema nervioso central (CNS) [2]. 
 
4.4 Marcadores indirectos 
El grupo de desarrollo de biomarcadores del ICR (Clinical PD Biomarker Group, Division of Cancer 
Therapeutics, Team Leader Dr. Michelle Garrett) ha demostrado cómo en muestras de células 
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mononucleares de sangre periférica (PBMC) o plasma enriquecido en plaquetas (PRP) se 
demuestra un incremento en la fosforilación de AKT relacionada con la inhibición farmacológica de 
AKT del inhibidor MK2206 [74]. Diversos biomarcadores farmacodinámicos de la cascada de 
señalización de PI3K/AKT/mTOR se han utilizado en diversos ensayos clínicos de fase I [82]. 
Específicamente, el grupo del ICR ha desarrollado un biomarcador farmacodinámico de la 
cascada de señalización PI3K/AKT/mTOR utilizando la tecnología Meso Scale Discovery (MSD ®) 
en plasma enriquecido con plaquetas que cumple con la normativa de buena práctica de 
laboratorio clínico (GCLP) y que se utiliza en diversos ensayos clínicos en adultos en el Royal 
Marsden Hospital [83]. Hasta la fecha, ninguno de estos biomarcadores se ha utilizado en la 
población pediátrica y su validez no ha sido demostrada..  
 
4.5 Muestras de medula ósea para desarrollar biomarcadores farmacodinámicos. 
Dado que el 80% de los pacientes con neuroblastoma de alto riesgo sufren metástasis en medula 
ósea [5, 86] y que muestras de medula ósea se obtienen rutinariamente como parte del proceso 
de estadiaje y estudio de la respuesta al tratamiento convencional, parece plausible utilizar dichas 
muestras como fuente de tejido tumoral para el desarrollo de biomarcadores. El grado de 
afectación de la medula ósea varía desde lo microscópico detectable solo con las técnicas más 
sensibles como citometría de flujo hasta altos porcentajes (superiores al 90%) en muchos casos 
en situación de recaída. 
Diversas metodologías como FISH (Fluorescent In Situ Hybridisation), RT-PCR (Real Time 
Polimerase Chain Reaction) o análisis de fosforilación de proteínas de diversas cascadas de 
señalización como PI3K/AKT/mTOR, IGF-1R, EGFR, PDGFR o Aurora kinasas entre otras 
requieren muestras tumorales de alta pureza. Por tanto, es preciso desarrollar un procedimiento 
para aislar y purificar células de neuroblastoma obtenidas de aspirados de medula ósea en niños 
afectos de neuroblastoma metastásico. 
 
4.6 Biomarcadores farmacodinámicos en ensayos clínicos pediátricos 
El número de ensayos clínicos pediátricos fase I/II que han incluido biomarcadores 
farmacodinámicos es muy limitado. El primer estudio utilizando el inhibidor de PDGFR (receptor 
del factor de crecimiento derivado de las plaquetas) imatinib en niños con tumores sólidos utilizo la 
expresión de la diana como medio de selección de pacientes (biomarcador predictivo), y solo 
fueron incluidos niños con alta expresión de PDGFR o c-Kit mediante inmunohistoquímica. No se 
encontró ninguna correlación con la respuesta al tratamiento [89]. 
Varios ensayos de fármacos frente a EGFR (receptor del factor de crecimiento epidérmico) han 
analizado la expresión de la diana terapéutica en tejido tumoral o han realizado estudios 
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mutacionales. Un ensayo fase I pediátrico de erlotinib no encontró correlación entre 
biomarcadores de activación de la cascada de PI3K/AKT o mutaciones de PTEN y PIK3CA y las 
respuestas al tratamiento antitumoral [90]. Análogamente, otro ensayo de combinación de erlotinib 
con temozolomida en niños con tumores sólidos refractarios o el ensayo clínico de cetuximab con 
irinotecan se encontró activación de las vías de señalización pero no una correlación con la 
respuesta clínica [91]. Dichos estudios intentaron identificar a los pacientes que más se 
beneficiarían de la inhibición de EGFR basándose en la presencia de mutaciones o activación de 
la vía de señalización en muestras recogidas al diagnóstico retrospectivamente. Estos estudios no 
demostraron resultados clínicos suficientemente prometedores para continuar el desarrollo de 
dichas terapias y la falta de biomarcadores farmacodinámicos nos impide profundizar en las 
razones de este fallo terapéutico. 
Dos estudios utilizando bevacizumab, un anticuerpo monoclonal frente a VEGF (Factor de 
crecimiento del endotelio vascular) en niños han incorporado de forma prospectiva biomarcadores 
farmacodinámicos indirectos en muestras de sangre periférica y con nuevas modalidades de 
imagen funcional. En el primer ensayo clínico fase I en niños, biomarcadores circulantes 
incluyendo células circulantes endoteliales (CEC) y células progenitoras endoteliales circulantes 
(CEP) y otros factores solubles como VEGF o b-FGF. El análisis de dichos biomarcadores de 
angiogénesis mostro una variabilidad inter-paciente significativa y no se observe correlación con el 
beneficio clínico [93]. Un segundo ensayo estudiando la combinación de bevacizumab con 
Irinotecan en niños con gliomas de alto grado o gliomas difusos de tronco demostró inhibición de 
la cascada de señalización de VEGF tras el tratamiento con bevacizumab: el análisis de la 
fosforilación de VEGFR en células mononucleares de sangre periférica mostro una reducción de la 
fosforilación e inhibición terapéutica en un grupo de pacientes. A pesar de demostrar inhibición 
farmacológica de la diana, el ensayo no encontró ningún beneficio clínico en los pacientes [94]. 
En el caso de vorinostat, un inhibidor de deacetilasas de histona (HDAC) el uso de biomarcadores 
farmacodinámicos ha servido para demostrar inhibición de la diana terapéutica y establecer la 
dosis del fármaco para su desarrollo clínico. En el estudio fase I pediátrico de vorinostat [95] se 
detecto acumulación de acetil-H3-histonas en células mononucleares de sangre periférica en los 
pacientes recibiendo las dosis más altas. En los pacientes que recibieron el nivel más elevado la 
acumulación de acetil-H3 persistió más de 24 horas en tanto que en los que recibieron niveles 
intermedios se observaron efectos transitorios (6 horas). En los niveles más bajos, no se demostró 
acumulación de acetil-H3.  
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4.7 Desarrollo de biomarcadores farmacodinámicos de la vía de señalización PI3K en 
neuroblastoma 
Se prevé que los fármacos dirigidos contra la vía de señalización PI3K/AKT/mTOR serán 
especialmente beneficiosos en los niños con neuroblastoma MYCN amplificado, aunque esta 
hipótesis debe ser testada en la práctica clínica.  
En este estudio se llevará a cabo una modificación de la tecnología MSD® para medir la inhibición 
de la diana PI3K en células de neuroblastoma aisladas de aspirados de médula ósea. Esta técnica 
será desarrollada antes de su implementación en próximos ensayos clínicos de inhibidores de 
PI3K/AKT/mTOR. La tecnología será asimismo validada en muestras clínicas de sangre para 
medir la inhibición de PI3K en plasma enriquecido con plaquetas.  
Asimismo, se desarrollará un ELISA basado en Europio para medir los niveles de oncoproteína 
MYCN total en células de neuroblastoma aisladas de aspirados de médula ósea antes de su 
implementación en próximos ensayos clínicos de inhibidores de PI3K/AKT/mTOR o de Aurora 
Kinasas.  
 
4.8 Estándares GCP y GCLP 
Los estándares de Buena Práctica Clínica (GCP) son un conjunto de regulaciones y 
recomendaciones éticas y científicas que se deben seguir para el diseño, conducta, recogida de 
datos y publicación de ensayos clínicos que incluyen la participación de seres humanos [96]. 
El cumplimiento de estos estándares asegura que los derechos, la seguridad y el bienestar de los 
participantes del ensayo clínico están protegidos, y además, que los resultados de los ensayos 
clínicos son fiables y precisos. 
Los principios de Buena Práctica Clínica se establecen en las Directivas Europeas de Ensayos 
Clínicos (2001) y Buena Práctica Clínica (2005) del Parlamento Europeo. 
Los principios de Buena Práctica de Laboratorio Clínico (GCLP) representan el punto de unión 
entre los sistemas de Buena Práctica Clínica y de Buena Práctica de Laboratorio. Proveen un 
marco regulador en cuanto a instalaciones, sistemas y procedimientos para asegurar que los 
análisis de laboratorio realizados en el curso de ensayos clínicos satisfacen el nivel de Buena 
Práctica Clínica en cuanto a fiabilidad, calidad e integridad del trabajo de laboratorio [100].  
Se aplica a todas las muestras manejadas durante la realización de un ensayo clínico e incluye: 
organización y personal, instalaciones, equipamiento, materiales, reactivos, procedimientos 
normalizados estándares (SOP), control de calidad, auditoria de calidad y almacenaje y protección 
de datos. 
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Estos principios fueron establecidos por la Asociación Británica de Control de Calidad en 
Investigación (BARQA) para asegurar el cumplimiento de GCP y GLP en ensayos clínicos 
desarrollados en el Reino Unido [100]. 
El Clinical PD Biomarker Group del Institute of Cancer Research es un laboratorio específicamente 
diseñado para cumplir con las regulaciones de GCP y GCLP con el objetivo de garantizar la 
máxima calidad en los análisis de biomarcadores farmacocinéticos y farmacodinámicos de los 
ensayos fase I y II de terapias moleculares que se realizan en el Royal Marsden Hospital / ICR.  
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Hypotheses and objectives 
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1. Aims 
The aims of this study are 
 To adapt pharmacodynamic biomarkers of the PI3K signalling pathway  
 To develop the methodology to isolate tumour cells from the bone marrow of children with 
neuroblastoma  
 To develop a pharmacodynamic biomarker using MYCN oncoprotein, a downstream key 
effector of the PI3K signalling pathway to detect target inhibition in children with 
neuroblastoma 
These assays will be of major value in future studies of agents targeting the PI3K/AKT/mTOR 
pathway and MYCN in neuroblastoma and other MYCN-driven malignancies. These assays will be 
first implemented in a paediatric phase I trial of the PI3K inhibitor GDC-0980 and a paediatric 
phase I trial of the PI3K/mTOR inhibitor BEZ235 due to open at The Royal Marsden Hospital and 
other Children‘s Cancer and Leukaemia Group (CCLG) phase I centres during 2013.  
 
2. Hypotheses 
 Neuroblastoma tumour cells isolated from bone marrow of patients can provide a valuable 
source of tumour material for pharmacodynamic biomarker assays.  
 Changes in phospho- and total protein signals for the PI3K pathway targets AKT, GSK3β 
and p70S6K in children can be detected in neuroblastoma cells in the bone marrow and in 
PRP (as a surrogate marker), and can be used as proof of targeted pathway inhibition 
following administration of PI3K inhibitors.  
 Reduction of the PI3K target oncoprotein MYCN in children can be detected using an 
Europium based technology and can be used as an indicator of downstream PI3K target 
modulation following administration of PI3K inhibitors. 
These hypotheses translate into the following objectives: 
 
3. Objectives 
1. Development and standardisation of a procedure for measurement of total and phospho 
protein signals of the PI3K pathway in children in platelet-rich plasma as a surrogate 
tissue 
2. Development and standardisation of an immunomagnetic separation procedure for 
isolation of neuroblastoma tumour cells from bone marrow samples  
3. Development and standardisation of a procedure for measurement of protein levels of 
downstream effector MYCN with an Europium-based ELISA in neuroblastoma tumour 
cells from bone marrow samples 
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4. Development and standardisation of a procedure for measurement of total and phospho 
protein signals of the PI3K pathway in children with neuroblastoma in tumour cells from 
bone marrow samples  
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Material and methods 
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1. Reagents  
Buffers 
PhosSTOP tablets for dilution in 10 ml (Roche Diagnostics,GmbH, Mannheim, Germany) 
CST lysis buffer (Cell Signalling Technology, Danvers, USA) 
Flow cytometry buffer: MACS BSA and auto-MACS Rinsing Solution (Miltenyi Biotec GmbH, Gladbach, 
Germany) 
Lysis buffer: 100% Cooking buffer (containing hydrochloric acid, sodium orthovanadate, Trizma base, 
sodium dodecyl sulfate (SDS) and water, The Institute of Cancer Research) 
BCA reagent A (Pierce Biotechnology, Rockford, USA) 
BCA reagent B (Pierce Biotechnology, Rockford, USA) 
Albumin standard (Pierce Biotechnology, Rockford, USA) 
Bovine serum albumin BSA (Sigma, Saint Louis, USA) 
Delfia 
®
 assay buffer (Perkin Elmer, Turku, Finland) 
Delfia 
®
 enhancement solution (Perkin Elmer, Turku Finland) 
Phosphate buffered saline (PBS) tablets (Dulbecco ‗A‘ Oxoid, Basingstoke, UK) 
20% Cooking buffer: dilute 1:10 10X lysis buffer (Cell Signalling Technology, Danvers, USA) in 100% 
Cooking buffer (see lysis procedure) 
0.1% Tween 20 solution. Dissolve 1mL Tween 20 (Sigma, Saint Louis, USA) into 1 L of water and mix 
MSD Blocker A, dry powder (Meso-Scale, Gaithersburg, USA) 
MSD Read Buffer T with surfactant (4x) (Meso-Scale, Gaithersburg, USA) 
MSD Tris Wash Buffer (10x) (Meso-Scale, Gaithersburg, USA) 
MSD Tris Lysis Buffer (1x) (Meso-Scale, Gaithersburg, USA) 
MSD Phosphatase inhibitor I (100x) (Meso-Scale, Gaithersburg, USA) 
MSD Phosphatase inhibitor II (100x) (Meso-Scale, Gaithersburg, USA) 
MSD Protease inhibitor solution (50×) (Meso-Scale, Gaithersburg, USA) 
MSD Blocker D-M (Meso-Scale, Gaithersburg, USA) 
MSD Blocker D-R (Meso-Scale, Gaithersburg, USA) 
Akt1/PKBα active (Upstate) (Meso-Scale, Gaithersburg, USA) 
Akt1/PKBα unactive (Upstate) (Meso-Scale, Gaithersburg, USA) 
 
Antibodies and MYCN standards 
Anti-human Disganglioside GD2, Mouse IgG2a, Clone 14.G2a (BD Pharmingen, San Jose, USA) 
APC-H7 Mouse anti-Human CD45 (BD Pharmingen, San Jose, USA) 
Goat polyclonal secondary antibody to Mouse IgG2a – heavy chain FITC (Sigma Saint Louis, USA) 
Eu-N1 goat anti-rabbit IgG (Perkin Elmer, Turku Finland) 
Anti-Mycn rabbit C-19 policlonal antibody SC-791 (Santa Cruz Biotechnology, Santa Cruz, USA ) 
Anti-Mycn monoclonal antibody B8.4.B (Santa Cruz Biotechnology, Santa Cruz, USA) 
Anti-Mycn monoclonal antibody OP13 (Calbiochem, Merck KGaA, Darmstadt, Germany) 
MSD SULFO-TAG anti total Akt Signalling antibodies (50x) (Meso-Scale, Gaithersburg, USA) 
MYCN peptide (Abcam, Cambridge, UK) 
MYCN lysate (OriGene, Rockville, USA) 
MYCN recombinant protein (Abnova, Taipei City, Taiwan) 
 
Immunomagnetic beads 
MACS Goat Anti-Mouse IgG2a+b MicroBeads (Miltenyi Biotec GmbH, Gladbach, Germany) 
FcR Blocking Reagent (Miltenyi Biotec GmbH, Gladbach, Germany) 
CD45 MicroBeads (Miltenyi Biotec GmbH, Gladbach, Germany) 
 
Plates 
NUNC 96-well plate (Thermo Scientific, Rochester, USA ) 
MSD MULTI-SPOTR 96-well Plate with phospho Akt Signalling antibodies attached (Meso-Scale, 
Gaithersburg, USA) 
MSD MULTI-SPOTR 96-well Plate with total Akt Signalling antibodies attached (Meso-Scale, Gaithersburg, 
USA) 
Immulon2HB 96 well polystyrene microtitre plates (Thermo Electron Corp, Thermo Scientific, Rochester, 
USA) 
 
Other materials 
Distilled sterile water, (The Institute of Cancer Research) 
Marvel dried skimmed milk, (Premier Brands, UK) 
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Lymphoprep (Axis-Shield, Oslo, Norway) 
MACS BSA (bovine serum albumin) stock solution (Miltenyi Biotec GmbH, Gladbach, Germany) 
auto-MACS Rinsing Solution (Miltenyi Biotec GmbH, Gladbach, Germany) 
 
Tubes and columns 
BD Vacutainer CPT Tubes (Beckton and Dickinson, Franklin Lanes, USA) 
Falcon tubes (The Institute of Cancer Research) 
1 mL and 500 l Eppendorf tubes (The Institute of Cancer Research) 
Pasteur pipettes (The Institute of Cancer Research) 
MS Columns (Miltenyi Biotec GmbH, Gladbach, Germany) 
CellTrics 100 M filters (Partec GmbH, Görlitz, Germany) 
Oncoquick ® (Greiner bio-one, Frickenhausen, Germany) 
Table 1, reagents 
 
2. Equipment 
Centrifuge, Eppendorf 5417R (Hamburg, Germany) 
MiniMACS Separation Unit (Miltenyi Biotec GmbH, Gladbach, Germany) 
MACS MultiStand (Miltenyi Biotec GmbH, Gladbach, Germany) 
Flow cytometer, BD LSR II flow cytometer, (Beckton and Dickinson, Franklin Lanes, USA) 
Heat block (Barloworld Scientific, Stone, UK) 
Heidolph Titramax 101 plate shaker (Heidolph Instruments GmbH, Schwabach, Germany) 
Wallac EnVision 2103 Multilable Reader (Perkin Elmer, Shelter, USA) 
Genlab 50 litre Incubator (Genlab, Widnes, UK) 
Mettler Toledo AX5 analytical balance (Mettler-Toledo, Greifensee, Switzerland) 
PerkinElmer EnVision 2103 Multilabel counter (Perkin Elmer, Shelter, USA) 
MSD SECTOR Imager 6000 (Meso-Scale, Gaithersburg, USA) 
Table 2, equipment 
 
3. Cell lines and murine tissue 
Kelly, SHEP, SHEP-WT and SHEP-DBL neuroblastoma tumour cell lines were obtained from the 
Neuroblastoma Drug Development Team at The Institute of Cancer Research (Ms. K. Barker). 
HeLa cells were used as a negative control for MYCN expression. (Table 3)  
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Cell line Clinical Features and Subtype MYCN gene copy number 
MYCN protein 
status 
GD2 
expression 
Kelly 1 year old boy 
Neuroblastic subtype 
MYCN amplified 
 
Very high protein 
levels 
High  
SHEP* 4 year old female, thoracic 
neuroblastoma with bone marrow 
metastases 
Substrate-adherent subtype 
MYCN diploid 
 
No detectable 
protein expression 
Low  
SHEP-WT* 4 year old female, thoracic 
neuroblastoma with bone marrow 
metastases 
Substrate-adherent subtype 
SHEP cells transfected 
with murine wild-type 
NMYC 
 
High protein levels Low  
SHEP-DBL* 4 year old female, thoracic 
neuroblastoma with bone marrow 
metastases 
Substrate-adherent subtype 
SHEP cells transfected 
with murine NMYC 
mutated at the S62 and 
T58 residues: MYCN 
double mutant,  
very high protein 
levels 
Low  
HeLa Adult female cervical cancer line No MYCN amplification 
 
No protein 
expression 
Negative 
Table 3, details of cell lines used in the study including origin, MYCN gene copy number, MYCN protein 
expression and surface expression of GD2. References [103-104] 
* SHEP cell lines are derived from parental SK-N-SH cells 
 
Neuroblastoma frozen tissue was obtained from TH-MYCN transgenic mice [20, 24] to be used as 
positive control for GD2 surface expression. Tumour tissue was obtained surplus to pre-clinical 
trials carried out by The ICR Neuroblastoma Drug Development team (Ms. Karen Barker). Animal 
welfare guidance and regulation was followed [105].  
  
Pharmacodynamic biomarkers in neuroblastoma, Lucas Moreno, January 2012 
55 
4. Patients 
Ethical and institutional approval was obtained from the RMH/ICR Committee for Clinical Research 
(CCR) and Research Ethics Committee (REC), protocol numbers CCR number 3358, REC number 
37167/84857/1/333. The study was sponsored by The Royal Marsden Hospital Clinical Research & 
Development. Patients, parents or legal guardians were given verbal and written information about 
the study and were asked to participate. Patients (when aged ≥16 years), parents or legal 
guardians provided written informed consent. See Appendix 1 for Letters of approval of the study 
and Appendix 2 for Patient and Parent Information Sheets and Informed Consent documents.  
The study opened for recruitment in January 2010. Samples were collected from January 2010 
until May 2011. Patients were included when aged 1 to 17.99 years, receiving treatment for a solid 
malignancy at the Children and Young People‘s Unit of The Royal Marsden NHS Foundation Trust 
and had a central venous line (to avoid venipunctures). Weight had to be ≥10 kg, Hemoglobin ≥9 
g/dl, Platelets ≥100x109/L and the patient had to be on a stable condition where blood sampling 
would not cause additional risks.  
One blood sample was taken from fourteen patients. Bone marrow aspirate samples were taken 
from five patients with metastatic neuroblastoma at different points in treatment. Table 4 
summarizes patient demographics of study CCR3358. Blood and bone marrow sample volumes 
were in accordance with European Medicines Agency guidance for volume of samples for research 
studies conducted in children [106].  
Age 
(years) 
Diagnosis Stage 
Stage in 
Treatment 
Last Chemotherapy  
Interval from prior 
chemotherapy 
(days) 
1.4 Low grade glioma Localised Chemo Vinblastine  7 
2.7 Neuroblastoma Metastatic Pre ASCT Busulfan/ Melphalan  >30 
2.7 Medulloblastoma Metastatic Chemo Methotrexate 5 
2.7 Neuroblastoma Metastatic Chemo 
Vincristine/ 
Cyclophosphamide  
5 
3.7 Wilms Localised Chemo Cyclophosphamide  21 
3.9 Neuroblastoma Metastatic Post ASCT Busulfan/ Melphalan  >30 
4.1 Medulloblastoma Localised 
Craniospinal 
radiotherapy 
None 
>30 
4.4 Neuroblastoma Localised Chemo Vincristine/ Doxorubicin  19 
4.7 Neuroblastoma Metastatic Chemo Cisplatin/ Vincristine  2 
10.3 Medulloblastoma Localised Chemo 
Cisplatin/ Vincristine / 
Lomustine   
21 
12.0 Neuroblastoma Metastatic Chemo Cyclophosphamide 28 
13.3 Supratentorial PNET Metastatic Post ASCT Thiotepa  25 
15.4 Medulloblastoma 
Localised 
relapse 
Chemo 
Cisplatin/ Vincristine / 
Lomustine  
2 
17.1 Rhabdomyosarcoma Localised Chemo 
Ifosfamide/ Vincristine/ 
Actinomycin D  
21 
Table 4, characteristics of the 14 patients enrolled on the study CCR3358. Chemo – Receiving 
chemotherapy, ASCT: Autologous Stem Cell Transplant, PNET: Primitive neuroectodermic tumour.  
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5. Processing of blood samples 
Three 2.7 ml tubes were collected in BD Vacutainer CPT ® tubes with sodium citrate and 
transported to the ICR Clinical PD Biomarker Group Laboratory at one timepoint.  
 The procedure followed was: 
 Immediately after collection, samples were centrifuged at 200 RCF at room temperature 
for 15 min. 
 After centrifugation, 600μl of plasma was extracted from each tube and pooled  (Figure 
2).  
 From this pooled plasma, 350μl aliquots of plasma were pipetted into four separate 
Eppendorff tubes.  
 150μl of PhosSTOP solution was added.  
 150μl of CST Lysis buffer was added.  
Each sample was mixed well and snap frozen at -80 C until processing.  
 
Figure 2, Scheme for peripheral blood sample collection 
Pharmacodynamic biomarkers in neuroblastoma, Lucas Moreno, January 2012 
57 
 
6. Processing of bone marrow samples 
Bone marrow aspirate samples from five patients with confirmed/suspected bone marrow 
involvement by neuroblastoma undergoing routine clinical bone marrow assessments were 
obtained. This procedure did not prolong the general anaesthetic times and did not increase the 
risks to the patient. Two ml sample of bone marrow aspirate sample was collected from each side 
(right and left iliac crest) on each occasion. EDTA, Preservative-free heparin, Oncoquick and BD 
Ficoll tubes were used for collection. Results of each collection type were analysed and are shown 
in ―Results‖. The majority of samples were collected in preservative-free heparin tubes.  
After collection, samples were transported to the ICR Clinical PD Biomarker Group Laboratory and 
Ficoll separation was performed to separate the cellular fraction that includes haematopoietic 
progenitors and neuroblastoma cells from plasma, red blood cells or platelets.  
Ficoll separation was performed:  
a) Manually by layering 2ml of the sample to 5 ml of Lymphoprep ® in 15mL Falcon tubes.  
b) In pre-prepared BD Ficoll tubes, where 2 to 5 ml of the sample were added directly to 
commercially available tube that contains a gel phase that separates the cellular 
fraction after centrifugation.  
Tubes were then centrifuged at 400 RCF for 20 minutes at room temperature and the mononuclear 
cell layer was extracted with a Pasteur pipette and passed through a 100 M filter.  
The cell layer was re-suspended in 10 mL of flow cytometry buffer and centrifuged at 1800 RCF for 
10 min. 
The cell pellet was re-suspended in 1 mL of flow cytometry buffer. 
Following this, procedure for immunomagnetic separation (below) was performed. Those samples 
were then stored at -80ºC to be used for measurement of the MYCN and PI3K/AKT pathway 
assays. 
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7. Immunomagnetic separation 
This method uses the Magnetic-activated cell sorting (MACS) technology.  
The technology uses MACS MicroBeads which are superparamagnetic particles of approximately 
50 nm in diameter. They are composed of a biodegradable matrix which does not alter the function 
or structure of labelled cells. Different types of magnetic beads bind to specific cell types. The cells 
are then run through a column placed in a MACS Separator where a high-gradient magnetic field is 
induced. Labelled cells bound to the MicroBeads are retained in the column while unabelled cells 
pass through and can be collected. Labelled cells can also be collected after removal of the 
column from the magnet.  
Two strategies can be used for cell separation: positive selection of desired cells or depletion of 
undesired cells.  
In the positive selection method, the MicroBeads are bound to the cell population of interest. Then 
the cell suspension is run through the column and the labelled cells of interest are bound to the 
magnet and then collected once the magnet is removed. There are commercially available 
MicroBeads for a number of cell populations (i.e. for stem cells there are CD133 MicroBeads) 
although none of them are designed for neuroblastoma, and cannot specifically isolate a 
population of neuroblastoma cells. There are indirect MicroBeads bound to biotin, fluorochromes or 
immunoglobulins which are then bound to a secondary antibody specific for the cell of interest. The 
indirect separation requires additional incubation, wash and centrifugation steps. 
In the cell depletion method, the MicroBeads bind to undesired cells. The cell suspension is then 
run through the column which retains the undesired labelled cells and the desired cells depleted 
from the unwanted cells are collected (i.e. to remove platelets from a cell suspension, CD61 
MicroBeads would be used).  
This technology is widely used for: 1) research purposes, such as isolation of circulating tumour 
cells [107] and 2) in the clinical setting for the separation of products of stem cell harvest for 
autologous or allogeneic stem cell transplant such as T-cell depletion [108]. Two different 
approaches were used: positive selection of GD2+ cells and negative depletion of CD45+ cells.  
GD2 is a membrane ganglioside present in the surface of neuroblastoma cells. It is expressed in 
virtually all neuroblastomas [104] and only anecdotal reports have described the loss of GD2 
expression in patients treated with anti-GD2 immunotherapy [103]. GD2 is not expressed by any 
haematopoietic cells [104]. CD45 is a pan-hematopoietic marker present in all haematopoietic 
cells. It is not expressed by neuroblastoma cells [109].  
 
7.1 Positive selection of GD2-labelled fraction 
Pharmacodynamic biomarkers in neuroblastoma, Lucas Moreno, January 2012 
59 
With this procedure, MACS Anti-Mouse IgG2a+b immunomagnetic beads were added and bound 
to a monoclonal antibody against GD2 (BD Pharmingen). Samples were run through a magnetic 
column where cells attached to the MicroBeads (labelled fraction) were retained and non-labelled 
cells were washed out. Labelled cells were then eluted from the magnetic field and collected as a 
cell suspension. The MicroBeads are biodegradable and do not alter the biological properties and 
viability of the neuroblastoma cells. (Figure 3) 
 
 
Figure 3, Schematic representation of the GD2 positive selection procedure: 1. the mononuclear cell layer 
containing haematopoietic nucleated cells and neuroblastoma cells is separated from plasma, platelets and 
red blood cells, 2. anti-mouse Ig magnetic beads bound to mouse anti-human anti-GD2 monoclonal antibody 
are added to the cell suspension and bind to neuroblastoma cells, 3. The cell suspension runs through the 
magnetic column and the labelled cells (GD2+ neuroblastoma cells) bind to the magnetic column. Unlabelled 
cells pass through and are discarded, 4. the magnet is removed and the labelled cells are collected. 
 
The procedure followed was:  
 Sample was centrifuged at 1000 RCF for 10 minutes at 4°C and the supernatant was 
discarded.  
 Sample was then re-suspended in 1mL MACS buffer and 100 µL were separated for flow 
cytometry (see below procedure for flow cytometry)  
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 The remaining sample was centrifuged at 1000 RCF for 10 minutes at 4°C and the 
supernatant was discarded.  
 The cell pellet was re-suspended in 60 µL of flow cytometry buffer and 20 µL of Fc blocking 
reagent and 1µL of anti-GD2 monoclonal antibody were added.  
 Sample was incubated for 30 minutes at 4°C and centrifuged at 300 RCF for 10 minutes at 
4°C.  
 The supernatant was discarded, sample washed with 1 ml of flow cytometry buffer and 
centrifuged at 300 RCF for 10 minutes at 4°C. 
 After discarding the supernatant, the pellet was suspended in 80 µL of flow cytometry buffer 
and 20 µL of goat anti-mouse IgG2a microbeads were added. 
 Sample was incubated for 15 minutes at 4°C, then centrifuged at 300 RCF for 10 minutes 
at 4°C, supernatant was discarded and cell pellet re-suspended in 1 mL of flow cytometry 
buffer.  
 Sample was then centrifuged at 300 RCF for 10 minutes at 4°C, supernatant discarded and 
cell pellet re-suspended in 500 µL of flow cytometry buffer. 
 The sample was loaded onto a Miltenyi column that had been previously prepared by 
rinsing with 500 μL of flow cytometry buffer. 
 The column was washed with 500 μL flow .cytometry buffer three times.  
 The column was removed from the separator. 1 mL of flow cytomtery buffer was then 
pipetted onto the column and immediately flushed with the plunger.  
 100 µL were separated for flow cytometry analysis.  
 The remaining sample was centrifuged at 14000 RCF at 4 ºC for 10 minutes, supernatant 
discarded and frozen to -80ºC for further analyses. 
 
7.2 Indirect selection by depletion of CD45+ cells 
With this procedure, immunomagnetic beads bound to anti-CD45 antibody (CD45 MicroBeads) are 
added to the sample which is run through the column. The labelled (undesired) cells are bound to 
the column while the desired cells are collected (CD45-). CD45 is universally present in 
haematopoietic cells and is not present in the surface of neuroblastoma cells [109]. Figure 4 
represents the CD45 depletion procedure. 
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Figure 4, Schematic representation of the CD45 depletion procedure: 1. the mononuclear cell layer 
containing haematopoietic nucleated cells and neuroblastoma cells is separated from plasma, platelets and 
red blood cells, 2. CD45-labelled magnetic beads are added to the cell suspension and bind to 
haematopoietic cells, 3. the cell suspension runs through the magnetic column and the labelled cells 
(CD45+) bind to the magnetic column, 4. unlabelled cells (CD45-) pass through the column and are 
collected.  
 
The procedure followed was:  
 Sample was centrifuged at 1000 RCF for 10 minutes at 4°C and the supernatant was 
discarded.  
 Sample was then re-suspended in 1mL MACS buffer and 100 µL were separated for flow 
cytometry (see below procedure for flow cytometry)  
 The remaining sample was centrifuged at 1000 RCF for 10 minutes at 4°C and the 
supernatant was discarded.  
 The cell pellet was re-suspended in 80 µL of flow cytometry buffer and 20 µL of CD45 
MicroBeads were added.  
 Sample was incubated for 15 minutes at 4°C and centrifuged at 300 RCF for 10 minutes at 
4°C.  
 The supernatant was discarded, sample washed with 1 ml of flow cytometry buffer and 
centrifuged at 300 RCF for 10 minutes at 4°C. 
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 Supernatant was then discarded and cell pellet re-suspended in 500 µL of flow cytometry 
buffer. 
 The sample was loaded onto a Miltenyi column that had been previously prepared by 
rinsing with 500 μL of flow cytometry buffer. 
 The unlabelled fraction through the column was collected.  
 100 µL were separated for flow cytometry analysis.  
 The remaining sample was centrifuged at 14000 RCF at 4 ºC for 10 minutes, supernatant 
discarded and frozen to -80ºC for further analyses. 
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8. Calculation of the purity of neuroblastoma cell suspensions by flow cytometry  
In order to establish the performance of each immunomagnetic separation methodology in 
providing cell suspensions enriched in neuroblastoma cells flow cytometry was used to measure 
the proportion of neuroblastoma cells out of the total mononuclear cell fraction.  
Flow cytometry was performed in 100 L samples taken before and after the immunomagnetic 
separation procedures. Flow cytometry was performed in the initial experiments spiking 
neuroblastoma cell lines in healthy volunteer blood and also in the bone marrow samples involved 
with neuroblastoma that were collected as part of this study.  
Flow cytometry analyses were always performed within 24 hours of the sample collection or 
immunomagnetic separation.  
Two-colour flow cytometry was used to differentiate neuroblastoma cells from haematopoietic cells. 
A primary monoclonal antibody against GD2 (BD Pharmingen) was incubated with a secondary 
antibody with FITC (Fluorescein isothiocyanate). A commercially available CD45 monoclonal 
antibody with APC-H7 (Allophycocyanin H7) was used to evaluate CD45 expression. Flow 
cytometry including both CD45 and GD2 has been previously described in the literature [110]. 
Although combinations of more colours have been reported to be more specific, for the purpose of 
this study, out of the clinical diagnostic and minimal residual disease settings, only these two 
antibodies were used [110]. 
Compensation controls were performed for every analysis for GD2-FITC and CD45-APC-H7. No 
unstained control was used. Titration experiments were performed for GD2-FITC. For CD45 
manufacturer´s recommendations were followed. Neuroblastoma Kelly cell lines, and 
neuroblastoma cells suspended from murine neuroblastoma tumours were used as positive 
controls. HeLa cell lines were used as negative controls.  
For the flow cytometry analysis, 100 L samples were taken from the cell suspensions before and 
after the immunomagnetic separation. They were incubated for 20 minutes with 5 L of anti-GD2 
mouse anti-human monoclonal antibody and 5 L of goat anti-mouse FITC at 4 C. Samples were 
then washed with flow cytometry buffer, centrifuged at 300 RCF at 4ºC for 5 minutes and 
supernatant discarded. The cell pellet was then resuspended in 100 L of flow cytometry buffer 
and 3 L of APC-H7 anti-CD45 and incubated for 20 minutes at 4 C. The cells were then washed 
with flow cytometry buffer, centrifuged at 300 RCF at 4ºC for 5 minutes and supernatant discarded. 
Cell pellets were then resuspended in 500 L flow cytometry buffer and kept at 4ºC until taken to 
the flow cytometer.  
Samples were analysed with the BD LSR II flow cytometer, (Beckton and Dickinson, USA) and at 
least 10,000 events were counted using the FACSDiva® software. Data was analysed with 
WinMDI® flow cytometry software (version 2.8). Neuroblastoma cells were positive for GD2 and 
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negative for CD45. Therefore, percentages of GD2+/CD45- and GD2-/CD45+ cells were calculated 
by using the following gating strategy.  
On a forward scatter (FSC-A)/side scatter (SSC-A) dot plot, the mononuclear cells were identified 
by region R1. In all other dot plots, only the cells lying in R1 were represented. On a forward 
scatter amplitude (FSC-A)/height (FSC-H) dot plot, the Region R2 was determined aiming to 
exclude non cellular events. Region R3 defined the GD2-/CD45+ cells (haematopoietic) and region 
R4 defined the GD2+/CD45- cells (neuroblastoma). Figure 5 represents the gating strategy used in 
this study. 
‗Purity’ was defined as the proportion of neuroblastoma events (R4 = GD2+/CD45-) out of the total 
gated cellular events (R3 + R4). 
 
 
Figure 5, Gating strategy for flow cytometry. The mononuclear cells were gated as R1 on a FSC-A/SSC-A 
density plot. Then the R2 gate aimed to include only cellular events on a FSC-A/FSC-H density plot (centre). 
On a CD45-APC-H7 (Y axis) / GD2-FITC (X axis) plot the two populations were gated as R3 (GD2-/CD45+ 
corresponding to haematopoietic cells) and R4 (GD2+/CD45- corresponding to neuroblastoma cells). 
 
Estimation of cell recovery with flow cytometry 
‗Recovery‘ was defined as the proportion of cells that can be identified after the immunomagnetic 
separation procedure out of the initial total cells (i.e. the cells that are not lost during the 
procedure). It was not possible to evaluate recovery with a cell counter and for this reason, an 
estimation of recovery was obtained from the flow cytometry data.  
For this estimation, we acquired flow cytometry data during 60 seconds in the samples before and 
after the immunomagnetic separation. The total number of gated events (R3+R4) after 
immunomagnetic separation divided by the total number of gated events before the 
immunomagnetic separation was used to provide an estimation of the cell recovery and hence, cell 
loses.  
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9. Cell lysis 
Prior to performing any protein assay, samples were thawed and lysed. The lysis of PRP samples 
followed the manufacturer‘s instructions (MesoScale Discovery) for the triplex AKT assay and used 
MSD lysis buffer.  
For the MYCN ELISA, pellets of cell lines and BM samples stored at -80ºC were thawed and lysed 
according to our institutional SOP for PBMC samples/cell suspensions. This lysis procedure had 
been optimised at our lab for several ELISA assays including the determination of HSP72 or 
4EBP1 and was therefore deemed suitable for the MYCN ELISA. During the optimisation phase of 
this process, it was found that the best results were achieved with the in-house lysis buffer (data 
not shown, unpublished data, Simon Heaton and Michelle Garrett, Clinical PD Biomarker Group at 
ICR). Details of the composition of this buffer (―cooking buffer‖) are given in Table 1.  
First, samples were defrosted on ice, 100 µL of lysis buffer (100% cooking buffer) were added to 
each sample and left at room temperature for 15 minutes. Then, samples were put on the heat 
block at 100ºC for 15 minutes, mixed well and centrifuged at 14000 RCF at 4ºC for 10 minutes. 
Finally, supernatant was collected, 4µL were spared for BCA analysis and the remaining sample 
was frozen at -80ºC. 
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10. BCA analysis 
After samples were lysed, the bicinchoninic acid (BCA) protein assay was performed to assess the 
concentration of total protein present in the samples. This would allow: 1) to assess the exact 
amount of total protein obtained after the immunomagnetic separation procedures, 2) to evaluate 
the losses in total protein caused by the immunomagnetic separation and 3) to normalize the 
protein assays to equal protein concentrations in order to achieve comparable results.  
The BCA assay is a sensitive assay for protein determination that takes advantage of the biuret 
reaction to form a coloured solution in the presence of protein that can subsequently be detected at 
562nm in a plate reader. The biuret reaction occurs when a blue coloured complex is formed when 
a peptide containing three or more amino acid residues chelates copper ions in an alkaline 
environment. The complex of Cu1+ bound with four to six peptide bonds exhibits light absorbsion 
proportional to the number of bonds. The assay intensifies the signal 100 fold through the binding 
of BCA to the Cu1+ ion to produce a purple colour and a linear colorimetric absorbsion at 562nm.  
To perform this assay, the BCA reagent was prepared at 50 parts (reagent A) with 1 part (reagent 
B). A 1:10 dilution of samples was then prepared (4 µL sample + 36 µL distilled water in a 500 µL 
Eppendorf tube). Then, a 1:100 dilution of Quality Control bovine serum albumin solution to a final 
concentration of 500mg/ml (2 µL QC stock + 198 µL distilled water in a 500 µL Eppendorf tube) 
was performed together with a 1:2 serial dilution (50μL of standard + 50μL distilled water) in 500 
µL Eppendorf tubes from a 100 μL bovine serum albumin stock (50 mg/ml). For the blank wells, 
distilled water was used.  
10 µL of standards, QCs and Blanks were added to a 96-well plate, as shown in Figure 6. For each 
lysed sample 10 µL were added to the first two wells, 5 µL to the next two and 2.5 µL to the final 
two for the 1/10, 1/20 and 1/40 dilutions. Then 200 L of the prepared BCA reagents (A+B) was 
added and the plate was incubated at 37ºC for 30 minutes. The plates were read on the Wallac 
EnVision 2103 Multilable Reader following protocol for BCA analysis. Figure 7 shows an example 
of the data generated calculating the total amount of protein for each lysate.  
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Figure 6 shows the plate lay-out for BCA analysis. The blue wells correspond to the nine standard albumin 
solution dilutions, the yellow wells to the Quality Control (QC) solution, the green wells to the blank (distilled 
water) wells and orange and purple to the different analysed samples (up to 10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 2 3 4 5 6 7 8 9 10 11 12
A
Standard 
Curve ( g/ml) 
2000 Sample 1 1/10 1/40 1/20 Sample 9 1/10
B
Blanks
1/20 Sample 4 1/10 1/40 1/20
C 1/40 1/20 Sample 7 1/10 1/40
D Sample 2 1/10 1/40 1/20 Sample 10 1/10
E
QC's
1/20 Sample 5 1/10 1/40 1/20
F 1/40 1/20 Sample 8 1/10 1/40
G Sample 3 1/10 1/40 1/20
H 1/20 Sample 6 1/10 1/40
250
500
7.8
1000
15.6
31.3
62.5
125
Date:
Assay:
Assay Details:
PlateID:
Pharmacodynamic biomarkers in neuroblastoma, Lucas Moreno, January 2012 
68 
 
 
 
Figure 7 shows the example of the excel worksheet generated after BCA analyses of four samples of lysates 
of Kelly, SHEP, SHEP WT and SHEP DBL cell lines. A standard curve is performed with the serial albumin 
dilutions and R
2
 is calculated. Also, the coefficient of variation is calculated for the Quality Controls (QC). The 
concentration in micrograms per 50 μl of lysate is plotted in the table at the bottom and a calculation of the 
volume of sample required for protein analysis normalized to 20 μg per 50 μl well of total protein.  
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11. MYCN ELISA 
This Enzyme Linked Immunoabsorption Assay (ELISA) uses Delfia technology. Sample, standard 
and quality controls are coated directly onto the plate. A primary antibody to the MYCN protein is 
then bound to the captured MYCN protein. Europium labelled goat anti-rabbit IgG is then bound to 
complete the sandwich. Excess label is washed off and an enhancement solution releases the 
captured europium. The free europium is highly fluorescent in the 615nm range and is the assay 
output. (Figure 8) 
                   
 
 
Figure 8 shows a diagram representing the sandwich two-phase ELISA for MYCN protein. The plate is 
coated with the capture anti-MYCN monoclonal antibody (B8.4) and the lysates are added (yellow oval 
‗MYCN protein‘). The liquid phase antibody is an anti-MYCN polyclonal antibody (SC-791) that is bound to 
Europium in a two-step process. 
 
Prior to the analysis all neuroblastoma samples (cell lines and bone marrow cell suspensions) 
required isolation and lysis (described above). Initially, a single phase ELISA was tested although 
further development showed lack of specificity and for this reason a two-phase (sandwich) ELISA 
was further developed as described in the ‗Results‘ (figure 8). The procedure described in this 
section is the two-phase ELISA after all steps of optimisation. For the initial one-phase ELISA only 
the SC-791 polyclonal anti-MYCN antibody was used. Other modifications such as the choice of 
monoclonal antibody are discussed in the ‗Results‘ section.  
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To perform the sandwich MYCN ELISA a 1:1000 dilution of the anti-MYCN monoclonal antibody 
(B8.4) was prepared in PBS and 100 µL were applied per well. The plate was covered and kept 
overnight at 4ºC. In the following morning, the plate was washed four times with Tween 20 (0.1%), 
blocked with 200 µL per well of Marvel 5% (powder milk) and incubated for 1 hour at 37 ºC. A 
standard solution of the MYCN commercial recombinant protein was prepared and dilutions were 
made (240, 200, 160, 120, 90, 60, 45 and 0 pg/μl of MYCN recombinant protein). For Quality 
Control, an in-house lysate of Kelly cells was used. Samples previously lysed were thawed and the 
required amount diluted in 20% cooking buffer following the BCA spreadsheet (Figure 7). 50 L of 
the Standard, QC and samples were added to the plate in duplicate. Figure 9 shows a typical plate 
layout. The plate was then incubated at 37ºC for 2 hours and washed four times with Tween 20. To 
each well, 50 µL of anti-MYCN rabbit antibody (1:1000) were added, incubated at 37ºC for 2 hours 
and washed four times with Tween 20. Then, 50 L of Eu-N1 goat anti-rabbit IgG (1:500 dilution) 
were added to each well, incubated 37ºC for 1 hour and washed four times with Tween 20. 
50 L enhancement solution were added to each well, the plate was shaken for 5 minutes on 
shaker at room temperature and the plate was read on the Envision machine at 615 nm. Figure 10 
gives an example of the standard curve generated with the serial dilutions of the MYCN 
recombinant protein. 
 
 
Figure 9 shows typical plate layout where the standard MYCN recombinant protein dilutions are represented 
in yellow, the quality controls in orange (high, medium and low quality controls are represented as HQC, 
MQC and LQC) and the patient samples in blue (up to 37 samples in duplicate).  
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Figure 10 shows the standard curve generated after analysing serial dilutions of MYCN recombinant protein 
with the sandwich ELISA. In this case, each dilution was analysed in four wells. Average, standard deviation 
(SD), coefficient of variation (CV) and the value of R
2
 are calculated for quality control purposes.  
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12. MSD triplex assay for the PI3K pathway  
In previous decades pharmacodynamic (protein) biomarker analyses were performed by Western 
blotting, and this technique has been found to have several disadvantages, including the laborious 
procedure that is very operator-dependent, the lack of reproducibility as well as the significant 
volumes of sample required for single protein analysis. The development of new technologies that 
allow to study multiple analytes in the same sample in a more reliable and reproducible way have 
revolutionised the field of pharmacodynamic biomarker assays and after thorough validation 
processes are now used in clinical trials [84, 111]. Meso Scale Discovery® (MSD®) has developed 
a number of kits where plates are pre-coated with multiple antibodies for several cell signalling 
pathways.  
For the MSD AKT triplex assay two plates (phospho and total signalling) that have been pre-coated 
with the capture antibodies for AKT, GSK3β*, and p70S6K* (*MSD kit specific) are provided. The 
sample and a solution containing the labelled detection antibodies (an anti-total AKT, GSK3β and 
p70S6K antibody with an electrochemiluminescent compound, MSD SULFO-TAG® label attached) 
are then added. 
Phosphorylated and total AKT, GSK3β and p70S6K present in the sample binds to the capture 
antibodies immobilized on the working electrode surface; recruitment of the labelled detection 
antibody by bound AKT, GSK3β and p70S6K completes the sandwich. 
 
 
Figure 11, the diagram on the left represents a well from the MSD phospho-triplex AKT plate where there are 
four spots, each coated with a phospho-antibody (pp70S6K, pGSK3β, pAKT) or blank (BSA). The diagram 
on the right represents the sandwich formed for the analysis of the lysates with the capture antibody coated 
to the plate and the SULFO-TAG
®
 antibody bound to the cell lysate. 
 
A MSD® Read Buffer that provides the appropriate chemical environment for 
electrochemiluminescence (ECL) is added and the plate is then loaded into an MSD® SECTOR® 
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Imager for analysis. Inside the SECTOR Imager, a voltage is applied to the plate electrodes that 
cause the labels bound to the electrode surface to emit light. The instrument measures intensity of 
the emitted light to produce a quantitative measure of the amount of phosphorylated and total AKT 
present in the sample. 
The MSD total and phospho-triplex analyses were carried out on lysates from the PRP samples 
collected from children with solid tumours and in lysates from neuroblastoma cell lines. The 
procedure was performed in parallel for phospho- and total triplex analyses: The lysates were 
divided in two, then two different plates were used (phospho- and total) and two antibody kits (Anti-
phospho Akt Antibody solution and Anti-total Akt Antibody solution). The required volume of each 
lysate was determined with the BCA assay as described before and normalised for a protein 
concentration of 20 μg of total protein per well. For this, the plates were blocked with 150 μL per 
well of Blocking Solution (600 mg Blocker A added to 20 mL Tris Wash Buffer) and incubated with 
shaking for 1 hour at room temperature. The plates were then washed 4 times with Tris Wash 
Buffer. 25 μL of each sample (lysate) was added and plates were incubated with shaking for 1 hour 
at room temperature. Antibody Dilution Buffer (1mL of Blocking Solution to 2mL of Tris Wash 
Buffer) was prepared. The plates were washed 4 times with Tris Wash Buffer and 25 μL per well of 
Detection Antibody Solution (60 µL 50x SULFO-TAG Anti-Total or Anti-Phospho Akt Antibody to 
2.94 mL of Antibody Dilution Buffer) were added, plates were incubated with shaking for 1 hour at 
room temperature and washed 4 times with Tris Wash Buffer. Read Buffer (5mL of 4X Read Buffer 
T with surfactant to 15mL of deionized water) was added and plates were imaged within 5 minutes 
in the SECTOR imager. Figure 12 shows an example of the results of the MSD analysis of PRP 
samples. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pharmacodynamic biomarkers in neuroblastoma, Lucas Moreno, January 2012 
74 
 
 
Figure 12 shows the results of the MSD total triplex analysis of PRP samples from patients 005 and 006 with 
raw data, the standard curve for total AKT, Quality Controls and the results of Total AKT, GSK3β and 
p70S6K.  
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13. Statistical methods 
The following statistical calculations were performed 
1. PRP data 
a. Median, range, mean and standard deviation of total and phosphorylated AKT, 
GSK3  and p70S6 were calculated for the two groups of adult and paediatric 
patients. 
b. The levels of each of the total and phosphorylated proteins were compared between 
children and adults, age (children vs. adolescents), histological diagnosis 
(neuroblastoma vs. other), time from prior chemotherapy (less than 20 days vs. ≥20 
days) and stage (localised vs. metastatic disease) using the t-Student test.  
2. Immunomagnetic separation 
a. Purity was calculated before and after immunomagnetic separation with flow 
cytometry as described in section 8 of the Methods [R3 events/(R3+R4 events)]. 
Median and ranges of purity were calculated for the different immunomagnetic 
separation procedures but no statistical comparisons were made.  
b. Recovery was estimated with flow cytometry as described in section 8 of the 
Methods [(R3+R4 events after separation) / (R3+R4 events before separation)]. 
Median and ranges of the recovery were calculated but no statistical comparisons 
were made.  
3. MYCN ELISA 
a. Sensitivity: using MYCN recombinant protein (Abnova®), a standard curve was 
established to determine the minimal level of MYCN protein that could be detected 
with the ELISA assay. Additionally, the minimal amount of total protein (measured 
by BCA analysis) and the minimal number of neuroblastoma cells required to obtain 
a detectable signal was established. 
b. Specificity: Positive and negative controls were used to establish specificity of the 
assay. Positive controls included: Kelly and SHEP-DBL cells. Negative controls 
included: HeLa and SHEP cells, peripheral blood mononuclear cells and bone 
marrow samples clear of neuroblastoma involvement. Those analyses were 
performed in parallel with Western blotting to confirm the results. 
4. MSD in neuroblastoma cells. For the characterization of assay signal ranges in 
neuroblastoma cell lines, descriptive statistics were used. Median, range, mean and 
standard deviation of total and phosphorylated AKT, GSK3  and p70S6 were calculated in 
cell lines and in spiking experiments in peripheral blood and bone marrow samples. Signal 
ranges before and after immunomagnetic separation were compared using the t-Student 
test.  
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For all values, 95% confidence intervals were calculated when appropriate. All p values were two 
sided. A p value <0.05 was considered statistically significant. All statistical calculations were 
performed using the SPSS 17.0 ® statistical software (Chicago, IL, USA). 
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14. Good Clinical Practice and Good Clinical Laboratory Practice compliance 
The study was conducted according to Good Clinical Practice (GCP) guidelines and regulations 
that apply to the United Kingdom. The research followed practice according to International 
Conference on Harmonisation (ICH), Good Clinical Practice (GCP), the Declaration of Helsinki, 
Research Governance Framework for Health and Social Care 2005, and the Human Tissue Act 
2004. All staff involved in the study abided with the Data Protection Act 1998 and also with the 
Confidentiality Code of Practice and Data Protection Policy and Procedure. Laboratory 
experiments were conducted following the guidelines for Good Clinical Laboratory Practice (GCLP).  
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Results 
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1. Measurement of total and phospho protein signals of the PI3K pathway in 
children in platelet rich plasma as a surrogate tissue 
 
Previous work performed at the ICR Clinical PD Biomarker Group has used the MSD triplex panel 
to measure total and phospho signals for the PI3K/AKT signalling pathway in platelet-rich plasma. 
This assay has been developed and validated pre-clinically [83, 85, 112] and clinically at our lab 
[74] and has been implemented in several adult phase I trials, some of which have already been 
finalised [74]. The choice of the MSD triplex assay offers a strong and comprehensive evaluation of 
the PI3K/AKT/mTOR pathway from AKT to downstream effectors mTORC1 and mTORC2.  
Validation work performed in our lab prior to this study included: a) Surrogate tissue optimisation 
that found that PRP was superior to PBMC as a surrogate biomarker for the PI3K pathway, b) 
Proof-of-principle in vitro experiments that showed how phospho AKT decreased and the phospho-
AKT/total-AKT ratio increased after treating U87MG malignant glioma cells with an AKT inhibitor, c) 
Proof-of-principle ex vivo experiments that showed that these changes can be also detected in 
PRP incubated with an AKT inhibitor, d) establishment of Quality Controls, Sensitivity and 
Specificity and e) Assay fit-for-purpose in a clinical trial, optimisation of sample collection, stability 
and lysis that led to an SOP to GCLP standards.  
In the first-in-man study of the AKT inhibitor MK2206 an AKT inhibitor [74], a dose dependency 
was observed and the PD assay results were used to guide dose selection and scheduling in the 
trial.  
Therefore the goal was to develop the MSD technology to assess the PI3K/AKT signalling pathway 
in PRP from children with solid tumours in order to implement this assay in the forthcoming 
paediatric trials of PI3K/AKT/mTOR inhibitors.  
As discussed in the Methods section, PRP was collected from 14 children with solid tumours within 
the ethically and institutionally approved RMH CCR 3358 single-centre study. For comparison, 
baseline measurements from 24 adults with advanced solid cancers treated at the Drug 
Development Unit of RMH were used.  
The results of the MSD AKT Triplex total and phospho-proteins in children and adults are shown in 
Figure 13 and Table 5.  
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Figure 13, Results of MSD Phospho and Total Triplex AKT assay. Figure on the left shows phospho-protein 
signals in paediatric vs. adult patients for pAKT, pGSK3β and pp70S6K. * p<0.05, ** p<0.01, *** p<0.001 
 
 
 
Age 
Group 
Mean 
Standard 
deviation 
p value 
Phospho 
protein 
signals 
pAKT 
Children 3963.85 3269.547 
0.186 
Adult 7853.96 10056.473 
pGSK3B 
Children 8109.69 7833.582 
0.001 
Adult 1940.79 2703.307 
pp70S6K 
Children 2697.15 3675.442 
0.002 
Adult 231.62 61.120 
Total 
protein 
signals 
AKT 
Children 11435.50 11736.476 
0.695 
Adult 10197.20 7357.307 
GSK3B 
Children 6512.62 7945.476 
0.001 
Adult 949.08 537.102 
p70S6K 
Children 2995.31 1743.713 
0.03 
Adult 1783.88 1445.649 
Table 5 summarizes mean and standard deviation of protein signals using the MSD multiplex total and 
phospho-AKT panel in children (n=14) vs. adults (n=24). Means were compared using the t-Student test. 
 
Total and phospho-AKT signals in children are within similar ranges compared to signals in adults. 
Phospho protein signals for GSK3  and p70S6K were 4.2-fold and 11.6-fold higher in children 
respectively (p=0.001 and p=0.002). Total protein signals for GSK3  and p70S6K were 6.9-fold 
and 1.7-fold higher in children (p=0.001 and p=0.03).  
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There was no statistically significant differences between signals (for all total and phospho-proteins 
analysed) when the children data were grouped according to histological diagnosis (neuroblastoma 
vs. non-neuroblastoma), stage (localised vs. metastatic), age group (children vs. adolescents older 
than 10 years) and the time interval from previous chemotherapy (greater compared vs. less than 
20 days from last chemotherapy).  
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2. Isolation of neuroblastoma cells from bone marrow samples 
 
2.1 Establishment of adequate methodology, standards and controls to assess enrichment 
methods 
 
2.1.1 Expression of GD2 in neuroblastoma with flow cytometry: positive and negative 
controls  
 The membrane ganglioside GD2 has been consistently reported to be expressed in 
neuroblastoma cells [103-104]. The objective was to ensure that flow cytometry using the 
monoclonal antibody 14.G2a (BD Pharmingen) bound to FITC is able to detect expression of GD2 
membrane ganglioside on neuroblastoma cells form Kelly cell lines or neuroblastoma tumours from 
the TH-MYCN transgenic mouse murine tumours [20].  
Using flow cytometry, cells from the Kelly cell line and neuroblastoma cells suspended from tumour 
samples of TH-MYCN mice expressed GD2 on 94.3 and 83.6% of the total cellular events 
respectively (Figures 14 to 16 and Table 6). On the contrary, GD2 expression was much lower in 
unstained Kelly cells and HeLa carcinoma cells (0.1 and 5.9% respectively). 
 
 
 Events gated GD2+ events % 
Unstained Kelly 7681 6 0.1 
Kelly 7530 7099 94.3 
HeLa 9245 542 5.9 
TH-MYCN 3464 2895 83.6 
Table 6 shows the raw data acquired in the flow cytometry experiments depicted in Figures 14, 15 and 16. 
Kelly cells stained and unstained with GD2-FITC, HeLa cells and neuroblastoma cells obtained from tumours 
in TH-MYCN mice [20] were analysed. 30000 events were analysed for each experiment. Events gated 
represents the ‗R1‘ gate shown in Figure 14 (corresponding to the neuroblastoma cells).  
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Figure 14 shows the flow cytometry experiments to determine the expression of GD2 on Kelly cell lines. A 
and B represent the unstained Kelly cell suspension, C and D represent the Kelly cell suspension stained 
with GD2-FITC. 
A and C represent the FSC (forward scatter) / SSC (side scatter) density plot where the R1 gate corresponds 
to the population of neuroblastoma cells excluding dead cells and debris. In B and D, the expression of GD2-
FITC is charted on the X axis and the quadrant quantifies the proportion of GD2 positive events. Without the 
GD2-FITC staining, only 0.1% of events were GD2+ (panel B). With the GD2-FITC staining, 94.0% of Kelly 
neuroblastoma cells in a cell suspension showed surface expression of GD2 (panel D).  
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Figure 15 shows the flow cytometry experiments to determine the expression of GD2 in HeLa cells. Panel A 
shows the FSC/SSC scatter plot where the same population used in the previous experiment (Figure 14) 
was gated in R4. Panel B shows the GD2-FITC expression in the X axis. Only 5.4% of the HeLa cells 
expressed GD2 in their surface. 
 
 
Figure 16 shows the flow cytometry experiments to determine the expression of GD2 in single cell 
suspensions from neuroblastoma tumours that develop in the TH-MYCN transgenic murine model [20]. 
Panel A shows the FSC/SSC scatter plot where the same population used in the previous experiments 
(Figures 14 and 15) was gated in R6. Panel B shows the GD2-FITC expression in the X axis. 82.7% of the 
tumour cells showed expression of GD2 in the surface.. 
 
 
Diluting the anti-GD2 14.G2a monoclonal antibody, GD2 expression progressively decreased with 
serial dilutions (from 91.8% for the pure antibody to 68.4% for the 1:20 dilution (Figure 17 and 
Table 7 for raw data). Therefore undiluted antibody was required to maximize the signal for the 
detection of GD2 expression. 
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Figure 17 shows the flow cytometry experiments to determine the expression of GD2 in Kelly cells using 
decreasing dilutions of the GD2-FITC antibody. The anti-GD2 antibody was used pure (5μL, panel A), and in 
1:5 (panel B), 1:10 (panel C) and 1:20 (panel C) dilutions. The figures show the expression of GD2-FITC in 
the right upper quadrant. The expression of GD2 decreased with the dilutions (91.3%, 87.6%, 78.6% and 
66.8%) and in all future experiments pure undiluted anti-GD2 antibody was used. 
 
Dilutions Events gated GD2+ events % 
1:1 7686 7058 91.8 
1:5 8888 7885 88.7 
1:10 7778 6255 80.4 
1:20 6896 4714 68.4 
Table 7 shows the raw data acquired in the flow cytometry experiments depicted in Figure 17. Kelly cell 
suspensions were stained with decreasing concentrations of anti-GD2 antibody (titration). 30000 events 
were analysed for each experiment.  
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2.1.2 CD45 expression in Peripheral blood mononuclear cells (PBMC) 
CD45 reacts with the isoforms of the leukocyte common antigen present on all human white blood 
cells, including lymphocytes, monocytes, granulocytes, eosinophils, and thymocytes whereas it is 
not expressed in neuroblastoma cells [110]. CD45 is a pan-haematopoietic cell marker. 
Peripheral blood was obtained from three adult healthy volunteers on four separate occasions.  
The expression of CD45 in peripheral blood mononuclear cells isolated by Ficoll separation with 
CD45-H7 (BD Pharmingen) by flow cytometry was determined. Haematopoietic cells derived from 
peripheral blood mononuclear cells showed high expression of CD45 (69.8%) and no expression of 
GD2 (0%), (Figure 18). A cell suspension of neuroblastoma cells from the Kelly cell line showed no 
expression of CD45 (0 out of 19489 events).  
 
 
Figure 18, shows the flow cytometry experiments to determine the expression of CD45 and GD2 in healthy 
volunteer haematopoietic cells. Panel A shows the FSC/SSC scatter plot where population of viable 
haematopoietic cells was gated in R1. Panel B shows the GD2-FITC expression in the X axis and the CD45-
APCH7 in the Y axis. 69.8% of isolated cells in R1 showed positivity for CD45. Total events 6974, gated (R1) 
6734. R3 gate (CD45 expressing cells) 4702 events, R4 gate (GD2 expressing cells) 4 events. 
 
 
2.1.3 Identification of neuroblastoma and haematopoietic populations with flow cytometry 
Spiking experiments of peripheral blood with neuroblastoma cells (Kelly cell line) were performed 
at different levels of involvement by neuroblastoma cells to mimic the clinical scenario of clinical 
bone marrow samples. 
Aliquots with 0.2, 0.5, 1 and 2 ml of Kelly cell suspension (106 cells/ml) were added to 5 ml of 
healthy volunteer peripheral blood. 
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Flow cytometry analysis of neuroblastoma cells spiked in peripheral blood showed two populations 
which were clearly differentiated (Figure 19). This served as a baseline to evaluate the two 
different immunomagnetic separation methods. 
 
 
Figure 19, shows the flow cytometry experiments to determine the expression of CD45 and GD2 in healthy 
volunteer peripheral blood spiked with Kelly cell lines (1:5 dilution). Panel A shows the FSC/SSC scatter plot 
where population of viable cells was gated in R1. Panel B shows the GD2-FITC expression in the X axis and 
the CD45-APCH7 in the Y axis. Two populations are identified. R3 represents the population of CD45+/GD2- 
cells (haematopoietic) and R4 represents the population of CD45-/GD2+ cells (neuroblastoma). In this figure, 
the R3 population (haematopoietic) comprises 61.9% of the total gated events and the R4 population 
(neuroblastoma) comprises 36.7% of the total gated events. Total events 63473, gated events (R1) 30231. 
R3 events (CD45+/GD2-) 23448, R4 events (CD45-/GD2+) 8809. 
 
 
2.2. Identification of the optimum immunomagnetic separation method: purity and recovery 
of isolated cell suspensions 
 
Several technologies have been used in adult cancer to identify circulating tumour cells and there 
are currently several very successful automated systems such as CellSearch® by Veridex [71, 113] 
or microchip technology [114]. However those methods are based on the selection of antigens, 
such as epithelial cell adhesion molecule (EpCAM) or cytokeratines 8, 18 and 19 present on adult 
carcinoma cells, which are not present in childhood malignancies. There are currently no 
commercially available kits that are able to separate/enrich neuroblastoma cells and therefore we 
aimed to develop a specific neuroblastoma assay that could be used in bone marrow and blood 
samples. 
The membrane ganglioside GD2 is strongly expressed by neuroblastoma cells and not by 
haematopoietic cells. In normal tissues it is only expressed in neural tissues (cerebellum and 
peripheral nerves) [104].  
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The objective was to achieve the maximum cell purity (% of neuroblastoma cells) and recovery 
(minimal cell losses) in an assay with the minimal possible complexity. This was important as 
ultimately the assay would need to be validated for use in clinical trials across multiple centres.  
 
2.2.1 GD2 positive selection 
Given the lack of commercially available MicroBeads for GD2 positive selection, an indirect 
methodology was used, by a two-step process adding the anti-human GD2 mouse monoclonal 
antibody (BD Pharmingen) to anti-mouse MicroBeads (Miltenyi Biotech).  
 
2.2.2 CD45 depletion  
Due to the availability of commercial CD45-labelled immunomagnetic beads, CD45 depletion is a 
quicker procedure as several steps are eliminated. In addition, with this methodology, the tumour 
cells (neuroblastoma cells) remain untouched. Hence, this procedure would be more suitable and 
reproducible for protein assays.  
 
2.2.3 CD45 depletion compared to GD2 positive selection in peripheral blood samples 
CD45 depletion, in spiking experiments of Kelly cells in healthy volunteer peripheral blood 
achieved purity above 90% in 4 out of 5 experiments, whereas none one out of the 4 experiments 
with GD2 positive selection achieved purity above 90%. (Table 8 and Figure 20) 
Average±SD post-separation purity was 84.88%±0.14 for CD45 depletion compared to 
51.48%±0.26 for GD2 positive selection (t Student, p=0.04).  
CD45 depletion achieved a median 6.2-fold (range 2.0-33.8) improvement in the purity of the 
neuroblastoma cell suspensions. GD2 positive selection achieved a median 5.1-fold (1.2-22.4) 
improvement in purity. 
Therefore CD45 depletion achieved higher purity and more consistent results. 
 
 
Pre separation  Post separation  -x fold increase  
CD45 depletion 
(n=5) 
2.4% 82.6% 33.8 
9.7% 61.3% 6.3 
14.7% 91.1% 6.2 
27.3% 97.0% 3.6 
46.7% 92.4% 2.0 
GD2 positive 
selection (n=4) 
2.4% 54.7% 22.4 
9.7% 84.2% 8.7 
14.7% 22.0% 1.5 
37.2% 45.0% 1.2 
Table 8 shows the proportion of neuroblastoma cells determined by flow cytometry (GD2+/CD45- events) out 
of the total gated events before and after the inmunomagnetic separation with CD45 depletion and GD2 
positive selection in peripheral blood samples from healthy volunteers spiked with different concentrations of 
neuroblastoma cells from the Kelly cell line. CD45 depletion showed achieved better purity in the cell 
suspensions.  
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Figure 20, shows the flow cytometry experiments to determine the best immunomagnetic separation 
methodology (GD2 positive selection vs. CD45 depletion). In all panels, the GD2-FITC expression is plotted 
in the X axis and the CD45-APCH7 in the Y axis. Two populations are identified, R3 represents the 
population of CD45+/GD2- cells (haematopoietic) and R4 represents the population of CD45-/GD2+ cells 
(neuroblastoma). Panel A shows a 1:10 cell suspension of Kelly cells into healthy volunteer peripheral blood 
before the GD2 positive selection and panel B shows the cell suspension after the GD2 positive selection. 
Before the separation, in panel A, neuroblastoma cells (R4) comprise 9.7% (2697 events) of the gated 
events (27686). After the GD2 positive selection, in panel B, neuroblastoma cells (R4) comprise 84.2% 
(3559 events) of the gated events (4225 events).  
Panel C shows a 1:5 cell suspension of Kelly cells into healthy volunteer peripheral blood before the CD45 
depletion and panel D shows the cell suspension after the CD45 depletion. Before depletion, in panel C, 
neuroblastoma cells (R4) comprise 27.3% (8809 events) of the gated events (32257 events). After depletion, 
in panel D, neuroblastoma cells (R4) comprise 97.0% (30774 events) of the gated events (31712 events).  
 
 
2.2.4 CD45 depletion in bone marrow aspirates 
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CD45 depletion was also performed in bone marrow samples spiked with neuroblastoma cells from 
the Kelly cell line (n=3) and clinical bone marrow samples (n=4). In bone marrow aspirates, CD45 
depletion achieved 2.5-fold (2.0-11.0) and 6.1-fold (2.8-9.3) improvement in purity of 
neuroblastoma cells in spiked BM and clinically involved BM samples respectively. (Table 9 and 
Figures 21 and 22) 
Average±SD post-separation purity was 64.77% ±0.05 for BM samples spiked with Kelly 
neuroblastoma cells and 76.85%±0.10 for BM samples from patients with neuroblastoma bone 
marrow metastases. (Figure 22) 
 
 
Pre separation Post separation -x fold increase 
BM spiked with 
Kelly (n=3)  
6.4% 70.6% 11.0 
25.9% 63.6% 2.5 
29.8% 60.1% 2.0 
BM with 
neuroblastoma 
(n=4)  
17.0% 47.8% 2.8 
10.1% 94.0% 9.3 
12.2% 86.7% 7.1 
14.7% 78.9% 5.4 
Negative BM‘s 
(n=4)  
No population identified 
 
Table 9 shows the proportion of neuroblastoma cells determined by flow cytometry (GD2+/CD45- events) out 
of the total gated events before and after the inmunomagnetic separation with CD45 depletion in normal 
bone marrow samples spiked with neuroblastoma cells from the Kelly cell line (n=3 experiments), clinical 
bone marrow aspirates involved with neuroblastoma cells (n=4) and clinical bone marrow aspirates not 
involved with neuroblastoma (n=3). CD45 depletion achieved great improvements in purity (above 60%) in all 
but one samples.  
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Figure 21, shows the flow cytometry experiments using CD45 depletion in bone marrow aspirates spiked 
with Kelly cells 1:4 (Panels A and B, before and after, respectively) and clinical bone marrow samples from a 
patient with neuroblastoma metastatic to the bone marrow (panels C and D, before and after, respectively). 
In all panels, the GD2-FITC expression is plotted in the X axis and the CD45-APCH7 in the Y axis. Two 
populations are identified, R3 represents the population of CD45+/GD2- cells (haematopoietic) and R4 
represents the population of CD45-/GD2+ cells (neuroblastoma).  
Before the CD45 depletion in the bone marrow sample spiked with Kelly cells, in panel A, neuroblastoma 
cells (R4) comprise 25.9% (5598 events) of the gated events (21572 events). After the depletion, in panel B, 
neuroblastoma cells (R4) comprise 63.6% (15115 events) of the gated events (23766 events).  
In a sample from a patient with metastatic neuroblastoma, before depletion, in panel C, neuroblastoma cells 
(R4) comprise 17.0% (579 events) of the gated events (3400 events). After depletion, in panel D, 
neuroblastoma cells (R4) comprise 47.8% (2059 events) of the gated events (4310 events).  
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Figure 22, represents the purity of neuroblastoma cells achieved after immunomagnetic separation using 
GD2 positive selection in peripheral blood spiked with neuroblastoma cells (PB-GD2) and CD45 depletion in 
peripheral blood spiked with neuroblastoma cells (PB-CD45), healthy bone marrow spiked with 
neuroblastoma cells (BM-CD45) and clinical bone marrow samples (BM-samples). Blue bars represent the 
average of all experiments in that category and red bars represent standard deviation. * p<0.05  
 
2.2.5 Recovery 
In order to estimate recovery with flow cytometry, GD2 positive selection and CD45 depletion were 
performed in two blood samples spiked with Kelly neuroblastoma cells with a 15% and 2.5% 
concentration of neuroblastoma cells. The total gated events collected over 60 seconds before and 
after the immunomagnetic separation were used to estimate recovery as per the formula described 
in the ‗Methods‘ section. 
For the spiking experiment with 15% concentration of neuroblastoma cells, 1.5 ml of Kelly cell 
suspension (containing 2.7x106 cells) were added to 5 ml of blood (containing 25x106 white blood 
cells). Using CD45 depletion 29.3% of cells were recovered compared to only 6.4% of cells 
recovered using GD2 positive selection.  
An estimation of total cell numbers that would be available for lysis and further protein assays was 
performed. Using CD45 depletion it was estimated that 7.9x105 viable cells could be isolated 
whereas only 1.7x105 viable cells could be obtained after GD2 positive selection. (Figure 23) 
For the spiking experiment with 2.5% concentration of neuroblastoma cells, 0.4 ml of Kelly cell 
suspension (containing 0.7x106 cells) were added to 5 ml of blood (containing 25x106 white blood 
cells). Using CD45 depletion 6.9% of cells were recovered compared to only 2.1% of cells 
recovered using GD2 positive selection.  
An estimation of total cell numbers that would be available for lysis and further protein assays was 
then performed. Using CD45 depletion it was estimated that 0.5x105 viable cells could be isolated 
whereas only 0.15x105 viable cells could be obtained after GD2 positive selection. (Figure 23) 
0%
20%
40%
60%
80%
100%
PB-GD2 PB-CD45 BM-CD45 BM-samples
* 
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Figure 23 shows an estimation of cell recovery with CD45 depletion (depicted ‗CD45‘ in red) and GD2 
positive selection (depicted ‗GD2‘ in green) in the two experiments spiking neuroblastoma cells in peripheral 
blood at two different concentrations, 15% and 2.5%. Each of the experiments with 15% and 2.5% purity 
(pre-separation) is represented in the X axis. The number of flow cytometry events (R3+R4) as described in 
the ‗Methods‘ is shown in the Y axis. Blue bars represent the sample before the immunomagnetic 
separation, red bars the samples after CD45 depletion and green bars the samples after GD2 positive 
selection. In the experiment using 15% purity as baseline, 29.3% of cells were recovered with CD45 
depletion vs. 6.9% of cells recovered with GD2 positive selection in the experiment using 2.5% as baseline 
purity, 6.9% of cells were recovered with CD45 depletion compared to 2.1% of cells recovered with GD2 
positive selection. Taking into account the known cell numbers used to set the experiments, the estimated 
cell numbers after CD45 depletion and GD2 positive selection are plotted on top of the bars. Mean±SD 
recovery was 18.1%±0.16 for CD45 depletion vs. 4.5%±0.03 for GD2 positive selection (p=0.35). 
 
Despite significant cell loses using both methods which were attributable to the manipulations of 
the procedure, CD45 depletion showed to be superior to GD2 positive selection. The estimated 
number of cells isolated after CD45 depletion was sufficient for protein analyses. Protein signals for 
the PI3K/AKT pathway and MYCN protein expression were detected in the lysates generated after 
CD45 depletion as is described in the relevant sections of the ‗Results‘ below. (Table 12 and 
Figures 28, 40 and 43) 
The GD2 positive selection required an additional step pushing the plunger manually to extract the 
labelled neuroblastoma cells fraction. This introduced a significant amount of variability. This was 
shown in an experiment with neuroblastoma Kelly cells only, where the same methodology was 
followed three times and the step where the plunger is pushed to detach the labelled cells from the 
column was performed differently: a hard push, a soft push and no push, just allowing dripping. 
Significant variability was seen with this step. (Figure 24) 
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Figure 24, shows an experiment with Kelly cell suspensions only before (‗Pre-isolation‘) and after GD2 
positive selection. The same GD2 positive selection was performed three times, only differing on the step 
that manually plunged the labelled cells from the magnetic column: the plunger was pushed hardly (‗Hard 
push‘), softly (‗Soft push‘) and the plunger was not used allowing the sample to drip (‗Allow drip‘). Significant 
variability in the recovery is seen with the three steps. The percentages shown are the average of five 
measurements of cell numbers.  
 
2.2.6 Linearity 
Previous reports developing methodologies for the detection of circulating tumour cells in 
peripheral blood demonstrated linearity although this had never been shown in tumour cells 
isolated from bone marrow samples [71, 107]. No linear relationship was found between the purity 
of neuroblastoma cells before and after the CD45 depletion procedure. (Figure 25)  
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Figure 25, shows the linearity of the purity of neuroblastoma cells before and after CD45 depletion. The X 
axis represents the purity of the samples before the immunomagnetic separation and the Y axis the purity of 
the samples after the separation. No linear relation was found, R
2
 = 0.09, not significant.  
 
In summary, the immunomagnetic separation experiments showed that in peripheral blood spiked 
with neuroblastoma cells, CD45 depletion achieved superior purity and better recovery compared 
to GD2 positive selection. Moreover, CD45 depletion was able to achieve high purity in bone 
marrow samples spiked with neuroblastoma cells and bone marrow samples from patients with 
involvement by metastatic neuroblastoma. 
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2.3. Optimization of sample collection and processing procedures 
In order to optimise the assay, several issues related to collection and processing of samples were 
studied.  
2.3.1 Collection tubes 
The performance of three methods to separate mononuclear cell fraction was compared:  
- A commercially available Ficoll collection tube (BD Vacutainer CPT®) where the Ficoll 
reagent is a solid gel permitting a 1-step Ficoll separation: once the blood or bone marrow 
is collected into the heparinised tube, the centrifugation is done immediately and the PBMC 
layer can be collected easily as is separated by the solid gel. (Figure 26) 
- A commercially available Oncoquick® tube which is a variation of a Ficoll separation 
method where the density gradient is optimised to obtain the best purity of tumour cells (as 
they have a specific density) [115-116]. (Figure 27) 
- Collection in heparinised tubes (preservative-free heparin) and manual Ficoll separation 
[117].  
 
 
Figure 26 shows the BD Vacutainer CPT
®
 Ficoll separation collection tubes. Panel A shows a schematic 
representation of the collection of blood before centrifugation. From bottom to top, the first layer is the 
density solution (Ficoll), and then a layer of Polyester gel and the blood collected. Panel B shows the tube 
after one step of centrifugation where (from bottom to top) the first layer is the red blood cells, followed by 
the granulocytes and the density solution, then the Polyester gel, density solution and the plasma with the 
mononuclear cell, platelets and tumour cells. Panel C shows a picture of the blood tube after centrifugation 
with the same layers than B.  
BA C
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Figure 27 shows a representation of blood with circulating tumour cells collected with Oncoquick tubes. A 
represents the sample before centrifugation, where blood is mixed with the tumour cells and separated by a 
porous barrier from the separation medium. B shows an intermediate snapshot during centrifugation where 
the red blood cells and leukocytes are accumulating in the bottom of the tube and C shows the final result 
after centrifugation where the fraction containing tumour cells and platelets is separated of the leukocytes 
and red blood cells by the separation medium.  
 
For this experiment, Kelly cells were spiked in peripheral blood with 25% purity. The collection with 
BD Ficoll tubes reproduced this level of purity achieving 25.9% purity (5598/15974 events) 
whereas Oncoquick tubes achieved 34.0% purity (7966/15473 events). In spiking experiments in 
peripheral blood it was found that Oncoquick tubes were able to provide a moderate improvement 
in the proportion of neuroblastoma cells within the same sample.  
However, when those tubes were tested with BM samples, it was found that clots occurred very 
frequently in this type of sample with both Oncoquick and BD Vacutainer CPT tubes. It was 
believed that the cause of this was the small amount of anticoagulant in these commercial tubes, 
as they are designed for whole blood and not for bone marrow collection. The production of clots 
had two major disadvantages: - clots blocked the magnetic column, therefore hampering the 
immunomagnetic separation procedure and also increased the contamination by red cells which 
then interferes other protein assays. (Table 10)  
Collection tubes Observations 
BD Vacutainer CPT tubes (n=4) Frequent clots, unable to process the sample 
Oncoquick (n=1) Frequent clots made unable to process the sample 
PFH tube, manual Ficoll (n=4) No clots, adequate cell suspension, longer processing time 
Table 10 shows clinical observations made when performing collection of bone marrow samples with BD 
Vacutainer CPT, Oncoquick and PFH tubes with a manual (2-step centrifugation) Ficoll separation. PFH: 
Preservative-free heparin. 
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Therefore the finally proposed collection method consisted of tubes with 1 ml of preservative-free 
heparin and a manual Ficoll separation given that the increase in anticoagulant would avoid clots 
and provide better cell suspensions.  
 
2.3.2 MS compared to LD columns  
One potential disadvantage of using the CD45 depletion procedure is that the amount of CD45 
positive events in a blood/bone marrow sample is very large and hence the column could be 
saturated impairing the ability to enrich the samples. This has been particularly relevant for the 
detection of methods to isolate circulating tumour cells which are very rare events [107]. Therefore, 
MS columns (standard) with LD columns (suitable for larger amounts of events) were compared in 
a peripheral blood spiking experiment with 2 ml samples (same volume as clinical BM samples).  
The same sample with a 36.5% neuroblastoma cells (1573/4308 events) was ran through two 
different columns. CD45 depletion achieved a purity of 77.0% (3904/4540 events) using the MS 
column and 57.0% purity using the LD column (538/944 events).  
For this volume of blood/bone marrow, the use of LD columns did not improve the purity or 
recovery of the experiment, therefore MS columns were chosen.  
 
2.3.3 Sample stability 
The ratio of the events that were gated in R1 (events that correspond to live cells that will be 
analysed with CD45 and GD2 to determine purity) and the total number of events detected by the 
system was compared. This ratio would estimate the proportion of ‗live‘ cells that are suitable for 
analysis and not dead cells or cellular debris. (Table 11) 
This ratio was compared between samples analysed within four hours on the same day and 
samples stored in the fridge at 4°C for 24 hours. The average ±SD ratio of R1 gated cells was 
51.7% ± 22.3 for samples processed in the same day and 11.1% ± 1.3 for those processed after 
24 hours (t Student, p=0.01). This demonstrated that samples can be processed up to 24 hours, 
but the proportion of cell losses significantly increases with time. 
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Table 11, shows the ratio between the events gated (R1) for analysis (viable cells) and the total events 
detected by the flow cytometer, reflecting the proportion of events that are cellular. The significant decrease 
in this ratio when processing was delayed 24 hours reflects significant cell loses.  
 Total events 
Events 
gated (R1) 
% of total 
events 
Processing in 
the same day 
within 4 hours 
(n=4) 
10000 
72032 
27345 
34711 
 
6915 
52419 
9636 
10357 
 
69.2% 
72.8% 
35.2% 
29.8% 
 
Processing 
after 24 h 
(n=4) 
261101 
265646 
234293 
240247 
 
26739 
26249 
28782 
29200 
 
10.2% 
9.9% 
12.3% 
12.2% 
 
Pharmacodynamic biomarkers in neuroblastoma, Lucas Moreno, January 2012 
100 
2.4. Quantification of protein content in isolated samples 
Pellets from cell lines with high cellular content were lysed up to a total volume of 200 μL of lysis 
buffer (100% ‗Cooking buffer‘). PB and BM samples provided smaller pellets and were lysed up to 
a volume of 100 μL of lysis buffer.  
BCA analysis was performed in all samples and the amount of total protein and volumes required 
from each sample was calculated to ensure that the immunomagnetic separation procedure was 
able to obtain sufficient amounts of tissue to carry out protein analyses. 
Mean, SD, median and range of total protein concentration for the BCA analyses performed in cell 
lines, spiked samples before and after the separation are shown in Table 12. Volume of lysate 
required for each of those categories is shown in Table 12 as well.  
 
 
Total protein concentration in 
the lysates (μg/μL) 
Sample volume 
Suitable for 4X 
protein analyses 
 Mean ± SD Median (range) Mean ± SD Median (range)  
Cell lines (n=19) 7.6 ± 4.3 6.3 (2.4 – 17.4) 10.2 ± 5.2 9.6 (3.5 – 25.0) 19/19 (100%) 
Samples Pre (n=7) 9.1 ± 6.5 8.4 (1.1 – 20.8) 10.3 ± 8.6 7.2 (2.9 – 28.3) 6/7 (85.7%) 
Samples Post (n=4) 5.7 ± 3.2 5.4 (2.4 – 9.7) 13.7 ± 8.3 11.7 (6.2 – 25.1) 3/4 (75%) 
Table 12, shows the results of BCA analysis on lysates obtained on cell lines and on samples before (Pre) 
and after (Post) immunomagnetic separation with CD45 depletion. Cell line lysates had a total volume of 200 
L and Pre- and Post- lysates had a total volume of 100 L The total protein concentration (2
nd
 and 3
rd
 
columns) in the 100 L was calculated as well as the sample volume (4
th
 and 5
th
 columns) that would be 
required to perform a protein analysis using 20 g per 50 l well of total protein which is our standard for 
protein assays. The column on the right (6
th
 column) shows the proportion of the samples that would have 
been suitable to perform four analysis, i.e. allow to perform two different protein assays in duplicate.  
 
There were no statistically significant differences in protein concentration and sample volume 
between cell line lysates compared to spiked samples: mean ± SD total protein concentration was 
7.6 ± 4.3 for cell lines vs. 7.9 ± 5.6 μg/μL for spiked samples (p=0.88) and mean ± SD sample 
volume was 10.2 ± 5.2 for cell lines vs. 11.5 ± 8.2 μL for spiked samples (p=0.59). 
There was a decrease in protein concentration (as well as an increase in required sample volume) 
in spiked samples post-separation compared to samples pre-separation, although those 
differences were not statistically significant: mean ± SD total protein concentration was 9.1 ± 6.5 
for samples pre-separation vs. 5.7 ± 3.2 μg/μL for samples post-separation (p=0.36) and mean ± 
SD sample volume was 10.3 ± 8.6 for samples pre-separation vs. 13.7 ± 8.3 μL for spiked samples 
(p=0.59). (Table 12 and Figure 28) 
All lysates were suitable to perform up to three protein assays (i.e. ELISA, MSD and the repeat of 
one of them), but samples would not allow to perform both assays in duplicate in all cases. (Table 
12) 
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Figure 28 shows the results of BCA analyses performed in lysates from cell lines (left), samples before the 
immunomagnetic separation (centre) and after the immunomagnetic separation (right) corresponding to the 
data detailed in Table 12. The Y axis represents the total protein concentration in μg/μL for the lysates 
obtained (200 μL for cell lines and 100 μL for the Pre- and Post- lysates). The box plot shows how the total 
protein concentration was lower (Table 12) in the samples after the immunomagnetic separation. 
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3. Development of a quantitative ELISA to measure total MYCN protein expression 
in neuroblastoma tumour cells from bone marrow samples  
 
The aim was to develop a quantitative/semiquantitative methodology to measure total MYCN 
protein levels in neuroblasts isolated from bone marrow samples. There are no commercially 
available technologies for this purpose and published reports on MYCN protein expression have 
used non quantitative methods – immunohistochemistry (IHC) or Western blotting (WB) [118-119]. 
There is a number of existing commercial polyclonal and monoclonal antibodies against MYCN. 
 
 The objectives were: 
1. To initially test a one-phase ELISA (with a MYCN polyclonal antibody) 
2. To establish a two-phase sandwich ELISA (combining a MYCN monoclonal with a 
polyclonal antibody) addressing issues with specificity with the one-phase ELISA.  
3. To establish sensitivity, standard curves and correlation with cell numbers  
4. To optimise of the assay by :  
 Determining the best protein concentration 
 Establishing adequate standards and quality controls 
 Determining the impact of the immunomagnetic separation procedure in the assay 
results 
 
3.1. Testing of SC-791 alone 
Initially an indirect ELISA approach using the MYCN polyclonal antibody SC-791 was tested as 
primary antibody against serial dilutions of MYCN recombinant protein (Abnova) and 
neuroblastoma cell lines and the results were compared to Western blotting. 
Western blotting with SC-791 showed that this antibody was be able to detect MYCN protein 
expression in those cell lines with known MYCN expression (Kelly and SHEP-DBL) and did not 
detect the protein in those with no expression of MYCN (SHEP and HeLa). (Figure 29)  
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Figure 29 shows a Western blotting for MYCN expression using the anti-MYCN polyclonal antibody SC-791. 
Five neuroblastoma cell lines and the ovarian cancer cell line HeLa were tested. The arrows represent the 
molecular weight bands (kDa). MYCN appears in two bands (two isoforms) between 60 and 80. As reported 
previously, Kelly, SY5Y and SHEP DBL cell lines showed high expression of MYCN whereas SHEP and 
HeLa cell lines were negative. Protein expression was weakly seen in SHEP WT.  
 
Therefore, the indirect ELISA on a Europium-based platform was used to measure MYCN 
recombinant protein (Abnova) and lysates of neuroblastoma cell lines. Although the standard curve 
using the recombinant protein showed a linear curve (R2=0.95, Figure 30) and a signal was 
detectable at small amounts of protein (Figure 31), the assay proved to lack specificity (Figure 32).  
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 Conc/well #1 #2 Average SD %CV 
MYCN 
protein 
(pg of 
recomb 
protein) 
350.0 13087 13050 13069 26 0.2 
263.7 13393 13326 13360 47 0.4 
175.0 6637 6379 6508 182 2.8 
131.3 6522 5257 5890 894 15.2 
87.7 4270 3723 3997 387 9.7 
44.0 1928 2053 1991 88 4.4 
22.0 1287 1452 1370 117 8.5 
0.0 573 562 568 8 1.4 
Figure 30, shows the standard curve for the one-phase ELISA performed with the anti-MYCN polyclonal 
antibody SC-791 with the raw data in the table below the figure (experiments in duplicate). Dilutions of the 
MYCN recombinant protein are shown in the X axis and Europium-counts on the Y axis.  
 
 
 Conc/well #1 #2 Average SD %CV 
Kelly 
lysate (pg 
of total 
protein) 
12300 6312 7365 6839 745 10.9 
6100 6649 5503 6076 810 13.3 
3000 4743 3407 4075 945 23.2 
1500 2532 2443 2488 63 2.5 
700 2039 1678 1859 255 13.7 
400 1441 1436 1439 4 0.2 
200 1073 1021 1047 37 3.5 
0 619 1222 921 426 46.3 
Figure 31 shows serial dilutions of a Kelly cell line lysate for the one-phase ELISA performed with the anti-
MYCN polyclonal antibody SC-791 with the raw data in the table below the figure (experiments in duplicate). 
Serial dilutions of the Kelly cell line lysate are shown in the X axis and Europium-counts on the Y axis.  
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  #1 #2 Average SD %CV 
Neuro-
blastoma 
cell lines 
(20 g/50 
l well 
total 
protein) 
SHEP 11611 9394 10502.50 1567.66 14.9 
SHEP-
MYCN 
6728 9624 8176.00 2047.78 25.0 
SHEP-
DBL 
4272 3210 3741.00 750.95 20.1 
Kelly 6767 9106 7936.50 1653.92 20.8 
PBS 487 586 536.50 70.00 13.0 
20%CB 408 416 412.00 5.66 1.4 
Figure 32, shows the specificity of the one-phase MYCN ELISA performed with the anti-MYCN polyclonal 
antibody SC-791. Four different cell lines were tested (X axis), two with high known expression of MYCN 
(Kelly and SHEP-DBL), one with low expression (SHEP-MYCN) and one with no expression of MYCN 
(SHEP), as well as two buffers, PBS and 20% ‗Cooking Buffer‘ (‗20% CB‘). The Y axis represents Europium 
counts. Raw data for the experiments in duplicate are shown below. The one-phase ELISA was not specific 
and was not able to differentiate the MYCN-expressing cell lines from the non-MYCN expressing ones.  
 
 
3.2. Testing of a sandwich ELISA 
Given that there was lack of specificity of the one-phase ELISA the assay was modified to a 
sandwich ELISA combining a monoclonal and a polyclonal antibody for the detection of MYCN. 
B8.4 monoclonal antibody produced stronger signals on Western blotting than the OP13 
monoclonal antibody. (Figure 33)  
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Figure 33, shows a Western blotting for total MYCN expression comparing the anti-MYCN monoclonal 
antibodies OP13 (A) and B8.4 (B). In both cases, the secondary anti-MYCN antibody was the polyclonal 
antibody SC-791. Five neuroblastoma cell lines and the ovarian cancer cell line HeLa were tested. The 
arrows represent the molecular weight bands (kDa). MYCN appears in two bands (two isoforms) between 60 
and 80. Non-expressing MYCN cell lines (SHEP and HeLa) were negative for expression and MYCN-
expressing cell lines (SHEP WT, SHEP DBL and Kelly) were positive.  
 
 
With the sandwich ELISA (Figure 34) cell lines with high expression of MYCN protein (Kelly) 
showed a 5.65-fold increase in signals compared to non-MYCN expressing cells (SHEP). A level of 
~2000 Europium counts was defined as background noise signal.  
 
BA
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 #1 #2 Average SD %CV 
SHEP 2396 2967 2681.50 403.76 15.1 
SHEP-
MYCN 
4279 3629 3954.00 459.62 11.6 
SHEP-
DBL 
7268 7711 7489.50 313.25 4.2 
Kelly 16293 14031 15162.00 1599.48 10.5 
HeLa 1914 1777 1845.50 96.87 5.2 
PBS 439 456 447.50 12.02 2.7 
20%CB 920 802 861.00 83.44 9.7 
Figure 34 shows the specificity of the sandwich MYCN ELISA performed with the anti-MYCN monoclonal 
antibody B8.4 and the polyclonal antibody SC-791. Five different cell lines were tested (X axis), two with 
known high expression of MYCN (Kelly and SHEP-DBL), one with low expression (SHEP-MYCN) and two 
with no expression of MYCN (SHEP and HeLa), as well as two buffers, PBS and 20% ‗Cooking Buffer‘ 
(‗20%CB‘). The Y axis represents Europium counts. Raw data for the experiments in duplicate are shown 
below. The sandwich ELISA showed specificity, where signals for Kelly cells (MYCN expressing) were 5.65-
fold higher than SHEP cells (MYCN non-expressing).  
 
 
3.3 Sensitivity, standard curves and correlation with cell numbers 
The lower level of sensitivity of the ELISA assay to detect MYCN protein was then assessed, and  
the signals obtained with MYCN recombinant protein were correlated with those obtained in Kelly 
cell lysates (Figure 35). This would allow an estimation of the minimum number of neuroblastoma 
cells required for a valid analysis of MYCN protein expression.  
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Raw data MYCN standard Curve 
Conc/well Standard Standard Average SD %CV 
pg/ L 1 2    
105.0 11174 14867 13021 2611 20.1 
79.1 8917 9164 9041 175 1.9 
52.5 6638 5973 6306 470 7.5 
39.4 5457 4791 5124 471 9.2 
26.3 3651 4272 3962 439 11.1 
13.2 2159 2138 2149 15 0.7 
6.6 1225 1519 1372 208 15.2 
0.0 487 586 537 70 13.0 
Raw data Kelly lysate dilutions 
Conc/well Standard Standard Average SD %CV 
pg/ L 1 2    
20.0 17950 15928 16939 1430 8.4 
10.0 10377 9839 10108 380 3.8 
5.0 5857 7660 6759 1275 18.9 
2.5 2335 1614 1975 510 25.8 
1.3 1091 993 1042 69 6.7 
0.0 695 753 724 41 5.7 
0.0 484 608 546 88 16.1 
Figure 35, shows the standard curve for the sandwich ELISA performed with the anti-MYCN monoclonal 
antibody B8.4 and the polyclonal antibody SC-791. Serial dilutions of MYCN recombinant protein (blue dots 
and line) and Kelly cell lysate (red dots and line) are plotted with their respective R
2
. The Y axis represents 
Europium (Eu) counts and the X axis increasing concentrations of MYCN recombinant protein. The raw data 
for both standard curves is shown in the table below the figure (experiments in duplicate).  
 
 
Table 13 shows the levels of MYCN protein expression correlated with the detected signals for 
Kelly cell lysates with different cell numbers. 
A level of 2000 Europium counts was considered background noise signal, as this was detected 
with lysates from cell lines without MYCN expression (HeLa or SHEP), (Figure 34). Therefore, 
detectable and distinguishable MYCN expression levels were detected from Kelly cells when 3.07 
x104 cells (or more) were present per 50 L well. 
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30.000 cells was established as the minimum number of neuroblastoma cells required for analysis 
of MYCN protein expression with this sandwich ELISA. This is equivalent to the signal generated 
by a 50 L solution containing 39.4 pg/ L of MYCN recombinant protein alone (i.e. 1.97 ng of 
MYCN protein).  
 
MYCN protein 
concentration 
MYCN 
protein 
signals 
Kelly 
lysate 
signals 
Total protein 
concentration 
per well 
Amount 
of cells 
per well 
pg/ L 
Europium 
counts 
Europium 
counts 
g per 50 L 
well 
x10
4
 
  16939 20 12.18 
105 13021    
79.1 9041 10108 10 6.14 
52.5 6306    
39.4 5124 6759 5 3.07 
26.3 3962    
13.2 2149 1975 2.5 1.54 
6.1 1372 1042 1.25 0.77 
0 537 724 0 0 
Table 13, shows a numeric comparison between Europium signals of the serial dilutions of MYCN 
recombinant protein with known concentration and Kelly cell lysates with known cell numbers shown in 
Figure 35. Given that the background signal was considered to be 2000 Europium counts (Figure 34), the 
following level where Europium signals were detectable above background was the 3.07 x 10
4
 cells per well 
(minimum level of sensitivity for cell lines). 
 
3.4 Optimisation of the assay 
3.4.1 Ideal protein concentration 
The next aim was to determine the level of total protein that maximises the differentiation between 
MYCN expressing and non-expressing cells. Therefore, signals obtained at 40, 20, 10 and 5 
micrograms per well for Kelly and SHEP cells were compared.  
The best protein concentration was 20 micrograms per well of total protein. At this level, the signal 
for MYCN positive cells was maximized while the background generated by SHEP levels was kept 
stable around 2000 Europium counts. (Figure 36)  
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  #1 #2 Average SD %CV 
Kelly/SHEP 
ratio 
40 g/well 
Kelly 20738 20820 20779 58 0.3 
5.14 
SHEP 3722 4365 4044 455 11.2 
20 g/well 
Kelly 17950 15928 16939 1430 8.4 
5.48 
SHEP 2974 3210 3092 167 5.4 
10 g/well 
Kelly 10377 9839 10108 380 3.8 
3.23 
SHEP 3121 3134 3128 9 0.3 
5 g/well 
Kelly 5857 7660 6759 1275 18.9 
2.56 
SHEP 2572 2711 2642 98 3.7 
Figure 36 shows the results of a MYCN sandwich ELISA (B8.4 monoclonal / SC791 polyclonal) to determine 
the best total protein concentration that maximises the signal difference between MYCN expressing and non-
expressing cells. Lysates expressing (Kelly) and non-expressing (SHEP) MYCN protein were tested at four 
different concentrations of total protein (5, 10, 20 and 40 g per 50 L well). Raw data is in the table below 
the figure, the column in the right shows the ratio between the average signal for Kelly lysate and SHEP 
lysate for each total protein concentration category. Experiments were performed in duplicate. The Y axis 
represents Europium counts. The figure shows how the concentration of 20 μg of total protein per 50 μg well 
(used for other ELISA in our lab) gives the maximum signal for Kelly cells (5.48-fold) while maintaining a 
lower background noise signal for SHEP.  
 
 
3.4.2 Establishing the best control for standard curve and quality control 
Several commercially available products were evaluated: Abnova MYCN recombinant protein, 
Abcam MYCN peptide and OriGene MYCN lysate to identify the best products to generate a 
standard curve and a robust quality control for further clinical development of the assay.  
The sandwich ELISA combining B8.4 and SC791 antibodies was not able to generate signals for 
the MYCN peptide or the MYCN lysate. However, MYCN recombinant protein gave strong signals 
and therefore was chosen to be used as the standard curve. (Figure 37)  
Additionally lysates from Kelly cell lines produced robust and constant signals at the concentration 
of 20 g/50 l well of total protein determined by BCA analysis. (Figure 39)  
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 #1 #2 Average SD %CV 
Kelly lysate 16293 14031 15162.00 1599.48 10.55 
MYCN Lysate 820 741 780.50 55.86 7.16 
Negative control for the lysate 564 542 553.00 15.56 2.81 
Abcam Peptide 540 497 518.50 30.41 5.86 
Abnova recombinant protein  
(Rec.Prot) 
31020 34537 32778.50 2486.89 7.59 
PBS 540 567 553.50 19.09 3.45 
20%CB 893 1125 1009.00 164.05 16.26 
Figure 37, shows the results of a MYCN sandwich ELISA (B8.4 monoclonal / SC791 polyclonal). Different 
commercially available MYCN products were tested to be used as controls for the ELISA: Origene MYCN 
lysate (‗lysate‘ and negative control ‗neg.control‘), Abcam MYCN peptide (‗peptide‘) and Abnova MYCN 
recombinant protein (‗Rec.Prot‘), and compared to an in-house Kelly cell lysate (‗Kelly‘). Raw data is in the 
table below the figure. Experiments were performed in duplicate. The Y axis represents Europium counts. It 
was found that the commercial lysate and the peptide were not recognised by the pair of antibodies in this 
ELISA and only MYCN recombinant protein gave detectable signals. 
 
 
3.4.3 Quality of the MYCN standard protein 
Unfortunately it was found that the signals obtained from MYCN recombinant protein experienced 
great variability after several cycles of freeze/thawing. (Figure 38)  
It was established that upon reception of the new batch of MYCN recombinant protein, aliquots of 
20 L would be performed and stored at -80 C. Prior to each analysis an aliquot is defrosted and 4 
L are required and diluted in 196 l of PBS. The remaining recombinant protein in the aliquot 
must be discarded. When smaller aliquots are made, the signals detected fall significantly and this 
justified the amount of recombinant protein required for each aliquot. 
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MYCN protein 
concentration 
Freeze/Thaw cycles 
pg/ul 1
st
 2
nd
 3
rd
 
105 13020.5 2305.5 1938 
79.1 9040.5 2031.5 1308 
52.5 6305.5 1471 1105 
39.4 5124 982.5 595 
26.3 3961.5 980 471 
13.2 2148.5 733 557 
6.1 1372 597.5 418 
0 536.5 586 375 
Figure 38 shows the result of a MYCN sandwich ELISA (B8.4 monoclonal / SC791 polyclonal). A standard 
curve using the same batch of MYCN recombinant protein was performed after one (blue dots and line), two 
(brown dots and line) and three (green dots and line) freeze/thaw cycles. This experiment showed that 
signals from Abnova MYCN recombinant decrease significantly after more than one freeze/thaw cycles and 
therefore after one use, this product should not be used for the standard curve after one freeze/thaw cycle. 
Values plotted in the line are the average of the duplicate analyses for each standard curve. Raw data 
(average of the duplicate analysis) is in the table below the figure. The Y axis represents Europium counts 
and the X axis increasing concentrations of MYCN recombinant protein. 
 
3.4.4 Reproducibility of the QC using Kelly lysates 
We analysed MYCN protein expression for four different batches of in-house Kelly lysates (in 
duplicate, all at 20 μg/50 μL well of total protein concentration) and obtained consistent results 
(average 16996.1, standard deviation 1750.34, coefficient of variation 10.3%). (Figure 39) 
Therefore, it was decided that in-house lysates from Kelly cell lines would be used as quality 
controls. Each time a new batch was lysed, a level for high, medium and low quality controls would 
be established de novo.  
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Batch 1 2 3 4 
Bar #1 #2 #3 #4 #5 #6 #7 #8 
Europium count 16293 14031 17950 15928 18462 19427 17950 15928 
Figure 39 shows the results of a MYCN sandwich ELISA (B8.4 monoclonal / SC791 polyclonal) performed 
using in four different batches of lysates (in duplicate, plotted in the X axis) from Kelly cell lines: 1 (#1 and 
#2), 2 (#3 and #4), 3 (#5 and #6) and 4 (#7 and #8). Y axis represents Europium counts. All four lysates 
showed similar range of signals. Average ± SD = 16996.13 ± 1750.34. 
 
 
3.4.5 Effect of the immunomagnetic separation in the detection of signals 
Finally, the aim was to demonstrate that the immunomagnetic separation procedure did not alter 
total MYCN protein signals. 
MYCN protein signals were not significantly altered after the immunomagnetic separation 
procedure using CD45 depletion (15162 ± 1599.48 compared to 15934.50 ± 1262.19, p=0.65). 
Additionally, signals were conserved when cells were spiked into peripheral blood and were 
different from peripheral blood (10.3-fold) alone [12950 ± 1736.55 for Kelly+peripheral blood vs. 
1254.5 ± 50.20 for peripheral blood alone (p=0.01)] or bone marrow alone (11.9-fold) [12950 ± 
1736.55 for Kelly+peripheral blood vs. 1083.50 ± 127.99 for bone marrow alone (p=0.01)]. (Figure 
40  
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 #1 #2 Average SD %CV 
Kelly 16293 14031 15162.00 1599.48 10.55 
Kelly Post 16827 15042 15934.50 1262.19 7.92 
Kelly+PBMC Post 14178 11722 12950.00 1736.65 13.41 
PBS 439 456 447.50 12.02 2.69 
20%CB 920 802 861.00 83.44 9.69 
PBMC alone 1219 1290 1254.50 50.20 4.00 
BM alone 993 1174 1083.50 127.99 11.81 
Figure 40 shows the result of a sandwich MYCN ELISA (B8.4 monoclonal / SC791 polyclonal) performed for 
Kelly cells (‗Kelly‘), Kelly cells after the immunomagnetic separation with CD45 depletion procedure (‗Kelly 
Post‘) and Kelly cells spiked in peripheral blood (‗Kelly+PBMC‘) after the CD45 depletion procedure. Signals 
for peripheral blood alone (‗PBMC‘) and bone marrow clear of neuroblastoma metastases (‗BM alone‘) are 
shown as well. PBS and 20% ‗cooking buffer‘ (‗20%CB‘) were used as negative controls. Raw data is in the 
table below the figure. Experiments were performed in duplicate. The Y axis represents Europium counts. 
The figure shows how total MYCN protein signals were not affected by the immunomagnetic separation 
procedure. 
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4. Measurement of total and phospho-protein signals of the PI3K pathway in 
children with neuroblastoma 
 
The MSD triplex AKT panel for total and phospho-protein signals has been used both in tumour 
tissues as well as surrogate tissues such as PBMC‘s or PRP at the ICR Clinical PD Biomarker 
Group [74, 83, 85, 112]. The present study aimed to measure total and phospho protein signals of 
the PI3K/AKT pathway in neuroblastoma cell lines as the first pre-clinical step to implement this 
methodology to measure pathway activation in bone marrow-derived neuroblastoma cells as a 
pharmacodynamic biomarker for early clinical trials of PI3K/AKT/mTOR inhibitors. This, in 
conjunction with MYCN protein expression would allow studying in humans the hypothesis that 
tumours expressing MYCN protein are extremely sensitive to PI3K/AKT/mTOR inhibition [24-25, 
120].  
 
Therefore, the objectives for this initial step of biomarker development were to demonstrate that:-  
- MSD technology is able to quantify total and phospho protein signals in neuroblastoma cell 
lines 
- MSD technology is able to quantify total and phospho protein signals in neuroblastoma cell 
lines spiked in peripheral blood and bone marrow samples and that signals are detectable 
and above background caused by PB and BM alone. 
- Immunomagnetic separation procedure does not significantly alter the total and phospho 
protein signals for the PI3K/AKT pathway detected with MSD technology. 
 
4.1 MSD analysis of neuroblastoma cell lines 
MSD multiplex Total and Phospho AKT Panel were performed in lysates from several 
neuroblastoma cell lines with high (Kelly and SHEP-WT) and no expression of MYCN protein 
(SHEP) using peripheral blood mononuclear cells as a negative control. 
The MSD platform was able to detect total and phospho signals for the three proteins (AKT, 
GSK3β and p70S6K).  
Signals for phospho-AKT (average Kelly 194 ECL counts, SHEP 223.5 ECL counts compared to  
196.5 for PBMC‘s) were within the background signal range. These results concur with previous 
published data by Opel et al. where a low phosphorylation of AKT had been previously described 
in neuroblastoma cell lines that are unstimulated (without IGF-1) using Western blotting [47]. 
(Figure 41)  
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  Kelly SHEP SHEP-WT PBMC 
Phospho 
protein 
signals 
pAKT 194 223.5 401.5 196.5 
pGSK3B 1261.5 692 380.5 326.5 
pp70S6K 1160.5 1013 2251 216 
Total 
protein 
signals 
AKT 816 968 817 203.5 
GSK3B 38519 13027.5 10413 648 
p70S6K 131017.5 51562 83109.5 4201.5 
 
Figure 41, shows the analysis of total and phospho protein signals of the PI3K/AKT pathway using 
MesoScale Discovery Triplex AKT kit in neuroblastoma cell lines. Electrochemoluminiscence counts are 
shown in the Y axis. Panel A shows phospho-signals for AKT, GSK3  and p70S6K and Panel B shows the 
total protein signals for AKT, GSK3  and p70S6K. Three cell lines (Kelly in blue, SHEP in green, SHEP-WT 
in beige) were analysed and compared to Peripheral Blood Mononuclear Cell lysates (‗PBMC‘ in purple). 
Experiments were run in duplicate and the table below the figure shows the raw data for the average of the 
two signals. Low phospho-AKT signals were found for the three unstimulated cell lines.  
 
4.2 MSD analysis of neuroblastoma cell lines spiked in peripheral blood and bone marrow 
samples 
Signals of total and phospho proteins of the PI3K/AKT pathway from lysates containing 
neuroblastoma Kelly cell lines (lysates of Kelly cells only and Kelly cells spiked into peripheral 
blood and bone marrow) were superior to signals from lysates of peripheral blood alone in all 
cases excepting for phospho-AKT. Phospho-AKT signals are known to be low in unstimulated 
neuroblastoma cells [47] and signals were similar to background (194 ECL for Kelly cells, 293 ECL 
for Kelly cells spiked in PB, 188 ECL for Kelly cells spiked in BM vs. 196.6 ECL for PBMC alone) 
and therefore could not be distinguished from those of healthy volunteer PBMC (Figure 42) 
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  Kelly PBMC PBMC+Kelly BM+Kelly 
Phospho 
protein 
signals 
pAKT 194 196.5 293 188 
pGSK3B 1261.5 326.5 3693.5 3626 
pp70S6K 1160.5 216 1420.5 1227.5 
Total 
protein 
signals 
AKT 816 203.5 791.5 448.5 
GSK3B 38519 648 22415 18699 
p70S6K 131017.5 4201.5 81166.5 59625 
 
Figure 42, shows the analysis of total and phospho protein signals of the PI3K/AKT pathway using 
MesoScale Discovery Triplex AKT kit in Kelly cells (‗Kelly‘ in blue), peripheral blood (‗PBMC‘ in green), 
peripheral blood spiked with Kelly (‗PBMC+Kelly‘ in beige) and bone marrow spiked with Kelly (‗BM+Kelly‘ in 
purple). Electrochemoluminiscence counts are shown in the Y axis. Panel A shows phospho-signals for AKT, 
GSK3  and p70S6K and Panel B shows the total protein signals. Experiments were run in duplicate and the 
table below the figure shows the raw data for the average of the two signals. For all total protein analyses, 
signals of Kelly cells and Kelly cells spiked in peripheral blood and bone marrow were clearly above 
background level of the peripheral blood alone. Also, for phospho-GSK3  and phospho-p70S6K lysates 
containing neuroblastoma cells had superior signals to peripheral blood alone. Only phospho-AKT signals of 
all the lysates were within the background noise level and hence no valuable results could be obtained for 
the analysis of phospho-AKT.  
 
4.3 Effect of the immunomagnetic separation on the MSD analysis 
Kelly cell lines spiked into peripheral blood and bone marrow samples underwent CD45 depletion. 
Lysates obtained before and after the CD45 depletion were analysed with MSD to assess the 
effect of the separation in total and phospho protein signals.  
There was a decrease in the total protein signals (average±SD 39300±44386 ECL counts before 
vs. 22800±27063 ECL counts after the immunomagnetic separation), reflected on a -0.24 log 
difference (p=0.36).  
There was an increase in the phospho protein signals (average±SD 1404±1360 ECL counts before 
vs. 1924±1870 ECL counts after the immunomagnetic separation) reflected on a +0.14 log 
difference (p=0.51) for the PI3K pathway after the separation (Figure 43). The immunomagnetic 
separation procedure impacted the total and phospho-protein signals for the PI3K/AKT pathway 
but the signals were detectable and consistent. 
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Figure 43, shows the analysis of total and phospho protein signals of the PI3K/AKT pathway using 
MesoScale Discovery Triplex AKT kit in Kelly cells spiked in peripheral blood before and after CD45 
depletion. Electrochemoluminiscence counts are shown in the Y axis. Panel A shows phospho-signals for 
AKT, GSK3  and p70S6K and Panel B shows the total protein signals. An increase in the mean phospho-
protein signals and a decrease in the total protein signals were documented although none reached 
statistical significance. 
 
These results showed that it is possible to use MSD technology to quantitatively assess the PI3K 
signalling pathway in bone marrow-derived neuroblastoma cells 
Once this initial work had been completed, the next steps would include MSD analysis of bone 
marrow samples involved with neuroblastoma to establish baseline signals in children with 
neuroblastoma. However, due to the staggered approach of this project, this part of the validation 
work has not been completed yet and hence is not presented.  
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Discussion 
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Despite advances in multimodal treatment of children with neuroblastoma, the long-term outcome 
is still poor and half of the children with high-risk disease will experience relapse and succumb [6, 
9]. Due to the recent increase in knowledge of neuroblastoma biology, novel drug targets have 
been identified [121]. In order to select the best agents to be taken forward for large multinational 
phase III clinical trials and eventually into the clinic, carefully conducted early clinical studies 
incorporating pharmacodynamic biomarkers are essential. 
Pharmacodynamic biomarkers of the PI3K pathway have shown proof of target inhibition in a 
number of early clinical trials [82, 122]. The model of the ―updated pharmacological audit trail‖ [77] 
provides a conceptual and practical framework to relate clinical observations with measurable end 
points. In the updated pharmacological audit trail biomarker assays are designed to test biological 
hypotheses in the pre-clinical and clinical settings. Each successive question when answered 
appropriately increases the likelihood of success of a clinical trial of a particular drug.  
Some examples of successful early clinical trials in adults with the use of pharmacodynamic 
biomarkers are the Phase I study of olaparib, a poly(ADP)-ribose polymerase (PARP) inhibitor 
[123], ARQ197, a MET inhibitor [111], MK2206, a pan-AKT inhibitor [74] or the combination study 
of MK8669 and MK0646 (an mTOR and an IGF-1R inhibitor respectively) [82].  
The use of pharmacodynamic biomarker assays in paediatric phase I studies poses several 
challenges: - the relatively rare frequency of childhood cancer requires that phase I studies are 
conducted in several sites (or even countries); the specific aberrations of childhood tumours which 
are not present in adult cancers, such as MYCN and the limitations of the procedures to obtain 
tissues that can be safely performed without compromising the children‘s wellbeing. 
The present study: 
a) Adapted a MSD ® assay employed in adult clinical trials for use in paediatrics using a 
surrogate tissue (platelet-rich plasma) that requires small amounts of blood and avoids 
invasive procedures to obtain tumour tissue. This assay is ready to be implemented in 
clinical trials. 
b) Developed an immmunomagnetic separation strategy that is able to isolate neuroblastoma 
cells from bone marrow aspirates with a high purity that is suitable for pharmacodynamic 
biomarker assays. This technique is ready for clinical use. 
c) Completed the pre-clinical development of a sandwich ELISA which will allow the 
quantification of total MYCN protein. This assay is at a clinical development phase. 
d) Completed the pre-clinical development of a MSD ® assay to measure total and phospho 
signals of the PI3K pathway in neuroblastoma cells. This assay is at a clinical development 
phase.  
The first part of the study aimed to adapt an existing pharmacodynamic biomarker assay, the MSD 
triplex AKT in PRP for use in children. Total and phospho signals of AKT, GSK3  and p70S6K 
Pharmacodynamic biomarkers in neuroblastoma, Lucas Moreno, January 2012 
121 
were analysed and results showed that the assay is fit-for-purpose. No differences were observed 
in AKT or phospho-AKT between a group of fourteen children with solid tumours receiving 
treatment at our institution and a group of 24 adults with advanced malignancies. The baseline 
signal levels for GSK3 , phospho- GSK3 , p70S6K and phospho-p70S6K were significantly higher 
in children than in their adult counterparts.  
This study was not designed to investigate the reasons for differences in baseline values in adults 
compared to children. The aim was to demonstrate that these proteins can be detected in the 
paediatric population, hence that the assay is fit-for-purpose for the population of children with solid 
tumours. Additionally, it was noted that for adults, the phospho-p70S6K signal was below the level 
of background detectable by the assay and it was not possible to use the pair phospho/total 
p70S6K for biomarker assessment. In the contrary, we have shown that both total and phospho-
p70S6K are detectable in children and therefore the assay could potentially offer a more thorough 
assessment of the pathway which will become relevant when assessing combination therapies 
This triplex assay provides a comprehensive assessment of the PI3K pathway including 
biomarkers of PI3K, AKT and mTOR activity and therefore will be useful to be included in a number 
of early clinical studies of drugs targeting PI3K, AKT, mTOR, TORC1 and TORC2 and for the study 
of feedback loops in the occurrence of resistance.  
This assay will be implemented as a tertiary endpoint in the upcoming phase I paediatric dose 
escalation studies of BEZ235 and GDC0980 (dual PI3K/mTOR inhibitors). 
Secondly, this study aimed to develop and validate methodology for the isolation of neuroblastoma 
tumour cells from bone marrow aspirates of patients with metastatic involvement by neuroblastoma. 
In experiments spiking neuroblastoma cells into peripheral blood, several immunomagnetic 
enrichment methods and sample collection procedures were evaluated. CD45 depletion was the 
best procedure to ensure cell suspensions highly rich in neuroblastoma cells. The procedure has 
been validated in a subset of clinical bone marrow samples where cell suspensions highly rich in 
neuroblastoma cells have been obtained. Moreover protein content obtained after the 
immunomagnetic separation was found to be sufficient to perform several pharmacodynamic 
analyses and the pre-clinical development of the other two biomarkers in this study showed that 
this approach would not affect the results in total and phospho signals for MYCN and the PI3K 
pathway.  
Although similar enrichment approaches have been piloted to obtain tumour material for genomic 
studies in neuroblastoma [87], this is the first study to show a comprehensive pre-clinical and 
clinical assessment of the different enrichment methodologies, aimed to obtain sufficient cell 
numbers for pharmacodynamic analyses.  
This assay has multiple applications. It will be routinely used in our institution to obtain and store 
neuroblastoma cells at different time points in treatment (i.e. at diagnosis, at relapse, during 
Pharmacodynamic biomarkers in neuroblastoma, Lucas Moreno, January 2012 
122 
molecularly targeted therapies and at the development of resistance) for different genomic, 
expression and pharmacodynamic analyses and will also be implemented in the upcoming phase I-
II studies enrolling children with neuroblastoma. Future developments will include the 
automatisation of the immunomagnetic separation procedure with the auto-MACS technology that 
will improve reproducibility and reduce processing times. This technology will be implemented as 
an ancillary biomarker sub-study of the Merck-led phase I paediatric clinical trials of MK8669 and 
MK0646 (mTOR and IGF-1R inhibitor respectively) and will be used as a source of PD biomarkers 
in the upcoming paediatric phase I trials of BEZ235 and GDC0980.  
The third part of the study aimed to develop a quantitative ELISA for total MYCN oncoprotein. 
There are no commercially available assays and MYCN is currently detected with Western blotting, 
a technique that is not quantitative, is time consuming, requires large volumes of samples and is 
operator dependant. Very few technical improvements in the detection of MYCN protein have 
occurred since the initial publications assessing MYCN protein expression in neuroblastoma [118-
119]. 
A sandwich ELISA that combines a mouse anti-MYCN monoclonal antibody for the solid-phase 
capture and a rabbit anti-MYCN polyclonal antibody for detection of antibody complexes has been 
developed using a Europium-based platform.  
The assay has been optimised and provided a specific and sensitive detection of MYCN protein. 
MYCN recombinant protein is used for the standard curve and lysates from Kelly cell lines will be 
used as Quality Controls.  
Future work will include the clinical validation of the assay in clinical samples and the comparison 
versus the currently established standard Western blotting that will be performed at a further stage 
of development in our institution. It is envisaged that this assay could also be tested as a predictive 
biomarker to select those patients with higher levels of MYCN protein expression that could 
potentially benefit more from MYCN-targeted therapies. Future work will also include the 
finalisation of Standard Operating Procedure (SOP), reproducibility and Good Clinical Laboratory 
Practice standards. This technology will be implemented as an ancillary biomarker sub-study of the 
Merck-led phase I paediatric clinical trials of MK-8669 and M-0646 (mTOR and IGF-1R inhibitor 
respectively) and will be used as a tertiary biomarker endpoint in the upcoming paediatric phase I 
trials of BEZ235 and GDC0980. 
Finally, this study aimed to adapt the MSD triplex AKT assay for use in bone marrow-derived 
neuroblastoma tumour cells. The methodology has been used in pre-clinical and clinical testing of 
molecularly targeted therapies of the PI3K/AKT pathway in adult cancers [83]. The initial pre-
clinical development of the assay for neuroblastoma cells was undertaken. This methodology was 
able to detect signals of the PI3K/AKT pathway in neuroblastoma cell lines and showed that the 
immunomagnetic separation procedure did not have a significant impact on the detection of total 
and phospho-protein signals.  
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Future work will be directed towards the validation of the methodology in human neuroblastoma 
cells obtained from bone marrow aspirates prior to the implementation in early clinical trials. 
Steps of biomarker 
development 
Before Now Next 
 PI3K in PRP 
Fully developed in 
adults 
None in children 
Ready to use in 
children 
Implementation in a clinical trial of a 
PI3K/AKT/mTOR inhibitor (BEZ235 
and GDC0980) 
Immunomagnetic isolation of 
neuroblasts from bone marrow 
samples 
None 
Discovery 
Pre-clinical and pilot 
clinical development 
Validation and optimisation within a 
clinical trial (MK8669 and MK0646) 
MYCN ELISA in bone marrow-
derived neuroblasts 
None 
Discovery 
Pre-clinical 
development 
Clinical development in patient 
samples 
Validation and optimisation 
PI3K in bone marrow-derived 
neuroblasts 
None 
Pilot pre-clinical 
development 
Further pre-clinical development 
Pilot clinical development 
Validation and optimisation in patient 
samples.  
Table 14, Steps of biomarker development achieved with the current study 
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Discusión en español 
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A pesar de numerosos avances en el tratamiento multidisciplinar del neuroblastoma, la 
supervivencia a largo plazo es todavía muy baja y más de la mitad de los niños con 
neuroblastoma de alto riesgo sufrirán recaídas y fallecerán por su enfermedad. Gracias a los 
nuevos avances en el conocimiento de la biología del neuroblastoma, se han encontrado nuevas 
dianas terapéuticas. La incorporación de biomarcadores farmacodinámicos en los ensayos 
clínicos fase I/II es esencial para seleccionar racionalmente los mejores fármacos a desarrollar y 
ser evaluados en grandes ensayos clínicos fase III que eventualmente serán utilizados en la 
práctica clínica.  
El uso de biomarcadores farmacodinámicos de la vía de señalización PI3K en ensayos clínicos 
fase I de fármacos dirigidos contra dianas terapéuticas de dicha vía ha permitido demostrar qué 
fármacos y en qué regímenes son capaces de inhibir de manera efectiva las dianas terapéuticas 
relevantes. El marco conceptual y práctico en el que las observaciones clínicas se correlacionan 
con objetivos concretos para desarrollar nuevos fármacos ha sido descrito en el concepto ―The 
Pharmacologic Audit Trail‖ (traducido como la ruta de auditoría de la investigación farmacológica) 
desarrollado por los profesores Paul Workman, Alan Ashworth y Johann De Bono en el Institute of 
Cancer Research de Reino Unido [77]. En este modelo, los biomarcadores se utilizan para 
demostrar hipótesis biológicas tanto en la investigación preclínica como clínica. De este modo, 
para un determinado fármaco o diana terapéutica, cada hipótesis biológica que se comprueba 
positivamente mediante los biomarcadores incrementa las posibilidades de éxito de un ensayo 
clínico de un medicamento determinado. El objetivo principal es, por tanto, que los biomarcadores 
ayuden a seleccionar los mejores fármacos en fases precoces, evitando así la administración de 
medicamentos ineficaces a pacientes que padecen cáncer en grandes ensayos clínicos. 
Algunos ejemplos de ensayos clínicos de medicamentos anticancerosos que han sido un éxito 
gracias al uso de biomarcadores farmacodinámicos han sido los ensayos fase I de olaparib, un 
inhibidor de PARP [123], ARQ197, un inhibidor de MET, MK2206, un inhibidor de AKT [74] o la 
combinación de MK8669 y MK0646 (inhibidores de mTOR y IGF-1R respectivamente) [82].  
El uso de biomarcadores farmacodinámicos en ensayos fase I pediátricos supone varios retos 
debidos a la baja frecuencia del cáncer infantil que requiere que dichos estudios se lleven a cabo 
en múltiples centros (o incluso países), las aberraciones moleculares o genéticas que son distintas 
en los tumores infantiles (p.ej. la amplificación del oncogén MYCN) y las limitaciones éticas y 
logísticas con los procedimientos que se pueden realizar de forma segura en la población 
pediátrica.  
En el estudio actual 
a) Se ha adaptado una tecnología utilizada en ensayos clínicos de adultos para su uso 
pediátrico utilizando un tejido de fácil acceso (plasma enriquecido en plaquetas). Dicha 
tecnología se encuentra preparada para ser implementada en ensayos clínicos pediátricos.  
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b) Se ha desarrollado una estrategia de separación inmunomagnética mediante la cual se 
pueden obtener suspensiones de células tumorales neuroblásticas de alta pureza aptas 
para ser utilizadas para analizar biomarcadores farmacodinámicos. Esta técnica esta lista 
para su uso clínico 
c) Se ha completado el desarrollo preclínico de un ELISA de dos fases para cuantificar la 
oncoproteína MYCN. Esta técnica está actualmente en fase de desarrollo clínico. 
d) Se ha completado el desarrollo preclínico de la tecnología MesoScale Discovery para 
medir señales de proteína total y fosforilada de la vía de señalización PI3K en células de 
neuroblastoma. Esta técnica está actualmente en fase de desarrollo clínico. 
La primera parte de este estudio estaba dirigida a adaptar un biomarcador farmacodinámico 
existente, usando el kit Triplex AKT de MSD® en plasma enriquecido en plaquetas para su uso en 
la población infantil. Se analizaron las señales de proteínas totales y fosforiladas de la vía de 
señalización de PI3K, incluyendo AKT, GSK3  y p70S6K, y los resultados han demostrado que la 
técnica es adecuada para este propósito y puede ser implementada en la población infantil. No se 
observaron diferencias en AKT o fosfo-AKT entre un grupo de catorce niños con tumores sólidos 
tratados en nuestra institución y un grupo de 24 pacientes adultos con tumores sólidos avanzados. 
Las señales basales de GSK3 , fosfo- GSK3 , p70S6K y fosfo-p70S6K fueron significativamente 
mayores en niños que en adultos.  
Este estudio no fue diseñado para investigar las razones que explican las diferencias entre los 
valores basales en niños comparados con adultos. El objetivo era demostrar que estas proteínas 
pueden ser detectadas en la población pediátrica y, por tanto, esta técnica es adecuada (fit-for-
purpose) para ser utilizada en dicho grupo. 
Además, los datos en adultos mostraron una señal de fosfo-p70S6K muy baja que impedía su uso 
como biomarcador. Por el contrario, en la población pediátrica, tanto fosfo-p70S6K como la 
proteína total fueron detectables en niños y por ello este análisis ofrece una evaluación más 
detallada y de la vía de señalización. Esto será especialmente relevante cuando se estudien 
combinaciones de terapias moleculares como un inhibidor de PI3K con in inhibidor de MEK.  
Esta técnica será utilizada en diversos ensayos clínicos de moléculas dirigidas contra PI3K, AKT, 
mTOR, TORC1 y TORC2, así como para estudiar las señales de retroalimentación negativa en 
caso de resistencia farmacológica. 
Esta técnica será implementada como un objetivo terciario en los ensayos clínicos de fase I de 
BEZ235 y GDC0980, ambos inhibidores duales de PI3K y mTOR que comenzarán en RMH/ICR 
durante 2013. 
En segundo lugar, este estudio fue diseñado para desarrollar y validar la metodología para aislar 
células tumorales de neuroblastoma de aspirados de medula ósea con afectación metastásica. En 
experimentos diluyendo células de neuroblastoma en sangre periférica, se compararon diversos 
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métodos de enriquecimiento inmunomagnético y se evaluó la metodología de colección de las 
muestras. La depleción de CD45 fue el mejor procedimiento para asegurar la mayor pureza de 
células de neuroblastoma en las suspensiones celulares. El procedimiento ha sido validado en 
una muestra piloto de aspirados de medula ósea donde se han obtenido muestras altamente 
purificadas con células de neuroblastoma. Además, el contenido proteico obtenido tras la 
separación inmunomagnética fue suficiente para la realización de diversos análisis 
farmacodinámicos. El desarrollo preclínico de otros dos biomarcadores durante este estudio 
demostró que esta estrategia de separación inmunomagnética no afectaría significativamente las 
señales de proteína total y fosforilada para la vía de señalización de PI3K y los niveles de MYCN. 
En un estudio piloto belga [87] se utilizaron métodos de separación inmunomagnética para 
estudios genómicos en neuroblastoma, pero este es el primer estudio que realiza un análisis 
minucioso comparando diversas estrategias de separación inmunomagnética dedicado a obtener 
muestras para análisis proteicos de biomarcadores farmacodinámicos. 
Esta técnica por tanto, tendrá diversas aplicaciones. Será utilizada rutinariamente en nuestra 
institución para obtener y almacenar células de neuroblastoma en diferentes puntos del 
tratamiento de los pacientes (por ejemplo, al diagnostico, durante la recaída y durante 
tratamientos con terapias moleculares dirigidas) para realizar análisis genómicos, de expresión y 
farmacodinámicos. Asimismo será implementada en los próximos ensayos clínicos fase I y II que 
incluyan pacientes con neuroblastoma.  
La fase de desarrollo inmediata a este estudio se centrara en la automatización del procedimiento 
con la tecnología auto-MACS que mejorara la reproducibilidad reduciendo los tiempos de 
procesamiento de las muestras.  
Esta tecnología será implantada en los sub-estudios de biomarcadores (objetivos terciarios) de los 
ensayos fase I de MK8669 y MK0646 (inhibidores de mTOR e IGF-1R respectivamente) 
esponsorizados por Merck que comenzaran a comienzos de 2012 y en los ensayos fase I 
pediátricos de BEZ235 y GDC0980. 
La tercera parte del estudio estaba dirigida a desarrollar un ELISA cuantitativo para cuantificar el 
contenido de la oncoproteína MYCN total. Actualmente, no hay técnicas comercialmente 
disponibles y se utiliza el Western blotting, que es una técnica no cuantitativa, laboriosa y muy 
dependiente del operador. Desde que los estudios iniciales cuantificando la proteína MYCN en 
neuroblastoma fueron publicados [118-119] no se han llevado a cabo mejorías en la tecnología de 
detección de MYCN. 
Durante este estudio, se ha desarrollado un ELISA tipo sándwich que combina un anticuerpo 
monoclonal anti-MYCN murino para la fase solida y un anticuerpo policlonal anti-MYCN de conejo 
para la fase liquida, mediante la utilización de una plataforma basada en Europio para la detección 
lumínica. 
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La técnica se ha optimizado hasta ofrecer una detección sensible y especifica de la proteína 
MYCN. Se utilizará proteína recombinante MYCN para realizar la curva estándar y lisados de 
células Kelly para realizar el control de calidad. 
Los planes de desarrollo en nuestra institución incluyen la validación clínica de la técnica en 
muestras clínicas y la comparación frente al patrón oro (gold standard) actual, el Western blotting. 
Además de su potencial como biomarcador farmacodinámico, esta tecnología se podría validar 
como biomarcador predictivo para seleccionar los pacientes con niveles muy elevados de 
expresión de proteína MYCN que podrían potencialmente beneficiarse selectivamente de 
tratamientos moleculares contra MYCN. Asimismo, se completara el procedimiento normalizado 
estándar (PNE). Esta tecnología será implantada en los sub-estudios de biomarcadores (objetivos 
terciarios) de los ensayos fase I de MK8669 y MK0646 (inhibidores de mTOR e IGF-1R 
respectivamente) esponsorizados por Merck que comenzaran el reclutamiento a comienzos de 
2012 y los ensayos fase I pediátricos de BEZ235 y GDC0980 durante 2012-2013. 
El objetivo final de este estudio fue la adaptación del MSD triplex AKT assay para su uso en 
células de neuroblastoma derivadas de muestras de médula ósea. Esta metodología se ha 
utilizado en el desarrollo preclínico de terapias dirigidas moleculares de la vía de señalización 
PI3K/AKT [83]. Se llevo a cabo el desarrollo preclínico inicial de dicha tecnología en células de 
neuroblastoma. Este método fue capaz de detectar señales de activación de la vía PI3K/AKT en 
líneas celulares de neuroblastoma y se demostró que los procedimientos de separación 
inmunomagnética no tenían un impacto significativo en la detección de señales de proteína total y 
fosforilada. 
La tecnología se continuara desarrollando la metodología en células humanas de neuroblastoma 
obtenidas de aspirados de medula ósea previamente a la incorporación en ensayos clínicos fase 
I/II. 
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Fases del desarrollo  Previamente Actualmente Desarrollo Futuro 
PI3K en plasma enriquecido 
con plaquetas 
Completamente validado e 
implementado en adultos. 
Ningún dato pediátrico 
Preparado para su uso en 
ensayos clínicos 
pediátricos 
Implementación en los 
próximos ensayos clínicos 
de inhibidores de 
PI3K/AKT/mTOR BEZ235 y 
GDC0980 (2012-2013) 
Separación 
inmunomagnética de 
células de neuroblastoma 
en medula ósea 
Ningún dato en 
neuroblastoma para 
biomarcadores proteicos 
Descubrimiento 
Fase preclínica  
Fase clínica piloto 
Validación y optimización 
durante el primer ensayo 
clínico (MK8669 y MK0646) 
ELISA para MYCN en 
células de neuroblastoma 
derivadas de aspirados de 
medula ósea 
Ningún dato pediátrico 
Descubrimiento 
Fase preclínica 
Desarrollo clínico en 
muestras de pacientes 
Validación y optimización 
PI3K en células de 
neuroblastoma derivadas 
de medula ósea 
Ningún dato pediátrico Desarrollo preclínico piloto 
Continuación del desarrollo 
preclínico 
Desarrollo clínico piloto 
Validación y optimización 
en muestras clínicas 
Tabla 14. Fases del desarrollo de los diversos biomarcadores en estudio 
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Conclusions 
1. This study developed pharmacodynamic biomarkers to accompany early clinical trials in 
childhood cancers and specifically for neuroblastomas driven by MYCN. 
2. The MesoScale Discovery® Triplex AKT assay was fit-for-purpose to measure the 
PI3K/AKT pathway in platelet-rich plasma of children with solid tumours 
3. Depletion of CD45+ cells was the best immunomagnetic separation procedure to isolate 
neuroblastoma cells from bone marrow aspirates 
4. CD45 depletion produced cell suspensions highly enriched in neuroblastoma cells that 
were suitable for protein assays  
5. A quantitative assay to assess levels of total MYCN protein in bone marrow-derived 
neuroblastoma cells has been developed 
6. The MesoScale Discovery® Triplex AKT assay can be used to evaluate the PI3K/AKT 
pathway in neuroblastoma cells 
7. This study has developed several biomarkers that will be able to provide a comprehensive 
assessment of pharmacodynamic changes after PI3K/AKT targeted therapy, to show proof 
of target modulation for PI3K, AKT and mTOR and downstream effects in MYCN protein 
levels for children with neuroblastoma.  
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Conclusiones en español 
1. Este estudio ha desarrollado biomarcadores farmacodinámicos para acompañar ensayos 
clínicos fase I/II en neuroblastoma derivado por MYCN 
2. Se demostró que la tecnología MesoScale Discovery Triplex® AKT es adecuada para su 
propósito (fit-for-purpose) y permitió medir la vía de señalización de PI3K/AKT en plasma 
enriquecido con plaquetas en niños con tumores sólidos 
3. La depleción de células CD45+ fue el mejor procedimiento de separación 
inmunomagnética para aislar células de neuroblastoma de aspirados de medula ósea 
4. La depleción de células CD45+ fue capaz de producir suspensiones celulares altamente 
enriquecidas en células de neuroblastoma que son adecuadas para análisis proteicos. 
5. Se ha desarrolló una tecnología cuantitativa para medir los niveles de proteína MYCN total 
en células de neuroblastoma derivadas de medula ósea 
6. Se demostró como la tecnología MesoScale Discovery Triplex® AKT puede ser utilizada 
para evaluar la vía de señalización de PI3K/AKT in células de neuroblastoma. 
7. Este estudio ha desarrollado diversos biomarcadores que proveerán un análisis 
comprehensivo de los cambios farmacodinámicos producidos con el tratamiento con 
inhibidores de PI3K/AKT, servirá para demostrar prueba de inhibición de la diana 
terapéutica para PI3K, AKT y mTOR así como efectos subsecuentes en los niveles de 
proteína MYCN en pacientes pediátricos afectos de neuroblastoma. 
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Appendix 1, Institutional letters of approval for patient sample collection (CCR3358 study) 
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Appendix 2, Patient information sheets and informed consent documents (CCR3358 study) 
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